<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE HTML>
<html xml:lang="en" xmlns="http://www.w3.org/1999/xhtml" lang="en">
  <head>
    <meta http-equiv="Content-Type" content="text/html;charset=utf-8"/>
    <title>HL7.EU.FHIR.GH\995d3971-b899-43bf-857d-98c26634796d - XML Representation - FHIR v4.1.0</title>

    <meta name="viewport" content="width=device-width, initial-scale=1.0"/>
    <meta name="author" content="http://hl7.org/fhir"/>

    <link rel="stylesheet" href="fhir.css"/>

      <!-- Bootstrap core CSS -->
    <link rel="stylesheet" href="assets/css/bootstrap-fhir.css"/>

      <!-- Project extras -->
    <link rel="stylesheet" href="assets/css/project.css"/>
    <link rel="stylesheet" href="assets/css/pygments-manni.css"/>
    <link rel="stylesheet" href="assets/css/jquery-ui.css"/>
  	<link rel="stylesheet" href="assets/css/prism.css"/>
      <!-- Placeholder for child template CSS declarations -->
    <link rel="stylesheet" href="assets/css/pcsp.css"/>

    <script src="fhir-table-scripts.js" type="text/javascript"> </script>

      <!-- HTML5 shim and Respond.js IE8 support of HTML5 elements and media queries -->
      <!-- [if lt IE 9]>
    <script src="assets/js/html5shiv.js"></script>
    <script src="assets/js/respond.min.js"></script>
    <![endif] -->

      <!-- Favicons -->
    <link sizes="144x144" rel="apple-touch-icon-precomposed" href="assets/ico/apple-touch-icon-144-precomposed.png"/>
    <link sizes="114x114" rel="apple-touch-icon-precomposed" href="assets/ico/apple-touch-icon-114-precomposed.png"/>
    <link sizes="72x72" rel="apple-touch-icon-precomposed" href="assets/ico/apple-touch-icon-72-precomposed.png"/>
    <link rel="apple-touch-icon-precomposed" href="assets/ico/apple-touch-icon-57-precomposed.png"/>
    <link rel="shortcut icon" href="assets/ico/favicon.png"/>
  </head>
  <body onload="document.body.style.opacity='1'">

	  <script src="assets/js/prism.js"></script>

    <style type="text/css">h2{--heading-prefix:"8.12"}
    h3,h4,h5,h6{--heading-prefix:"8.12"}</style>
    <div id="segment-header" class="segment">    <!-- segment-header -->
      <div class="container">    <!-- container -->
        
        <div id="hl7-nav">
          <a no-external="true" id="hl7-logo" href="https://www.gravitatehealth.eu/">
            <img src="assets/images/logo-header.jpg" alt="Visit the Project website" height="60"/>
          </a>
        </div>
   <!-- <div id="family-nav">
          <a id="family-logo" no-external="true" href="https://www.pancare.eu/projects"><img height="40" alt="Visit the PanCareSurPass website" src="assets/images/who-logo-www.jpg"/> </a>
        </div> -->
        <div id="hl7-search">
          <a no-external="true" id="hl7-search-lnk" href="http://hl7.org/fhir/search.cfm"><img src="assets/images/search.png" alt="Search FHIR"/></a>
        </div>


        <div id="ig-status">
          <p><span style="font-size:12pt;font-weight:bold">Gravitate Health FHIR Implementation Guide</span><br/>0.1.0 - CI Build</p>
        </div>
      </div>   <!-- /container -->
    </div>    <!-- /segment-header -->

    <div id="segment-navbar" class="segment">    <!-- segment-navbar -->
      <div id="stripe"> </div>
      <div class="container">    <!-- container -->
          <!-- HEADER CONTENT -->

        <nav class="navbar navbar-inverse">
            <!-- status-bar -->
          <div class="container">
            <button data-target=".navbar-inverse-collapse" data-toggle="collapse" type="button" class="navbar-toggle">
              <span class="icon-bar"> </span>
              <span class="icon-bar"> </span>
              <span class="icon-bar"> </span>
            </button>
            <a href="http://build.fhir.org/index.html" class="navbar-brand hidden">FHIR</a>
            <div class="nav-collapse collapse navbar-inverse-collapse">
                <!-- menu.xml -->

<ul class="nav navbar-nav">
  <li>
    <a href="index.html">IG Home</a>
  </li>
  <li>
    <a href="toc.html">Table of Contents</a>
  </li>
  <li class="dropdown">
    <a data-toggle="dropdown" href="#" class="dropdown-toggle">Contextual information information
      <b class="caret"></b>
    </a>
    <ul class="dropdown-menu">
      <li>
        <a href="connections.html">Connections</a>
      </li>
      <li>
        <a href="ePI-structure.html">ePI structure</a>
      </li>
      <li>
        <a href="use-case-example.html">Use Case</a>
      </li>
    </ul>
  </li>
  <li class="dropdown">
    <a data-toggle="dropdown" href="#" class="dropdown-toggle">Capability Statements
      <b class="caret"></b>
    </a>
    <ul class="dropdown-menu">
      <li>
        <a href="CapabilityStatement-capability-statement-ema.html">SmPC / PL</a>
      </li>
    </ul>
  </li>
  <li>
    <a href="artifacts.html">Artifact Index</a>
  </li>
  <li class="dropdown">
    <a data-toggle="dropdown" href="#" class="dropdown-toggle">Support
      <b class="caret"></b>
    </a>
    <ul class="dropdown-menu">
      <li>
        <a href="http://hl7.org/fhir/R4/index.html">FHIR Spec</a>
      </li>
      <li>
        <a href="downloads.html">Downloads</a>
      </li>
    </ul>
  </li>
  <li>
    <a href="copyright.html">Copyright</a>
  </li>
</ul>
            </div>    <!-- /.nav-collapse -->
          </div>    <!-- /.container -->
        </nav>    <!-- /.navbar -->
        <!-- /HEADER CONTENT -->
      </div>    <!-- /container -->
    </div>    <!-- /segment-navbar -->
      <!-- status-bar -->

    <div id="segment-breadcrumb" class="segment">    <!-- segment-breadcrumb -->
      <div class="container">    <!-- container -->
        <ul class="breadcrumb">
          <li><a href="toc.html"><b>Table of Contents</b></a></li><li><a href="artifacts.html"><b>Artifacts Summary</b></a></li><li><b>995d3971-b899-43bf-857d-98c26634796d</b></li>

        </ul>
      </div>    <!-- /container -->
    </div>    <!-- /segment-breadcrumb -->

    <a name="top"> </a>
    <div id="segment-content" class="segment">    <!-- segment-content -->
      <div class="container">    <!-- container -->
        <div class="row">
          <div class="inner-wrapper">

<div style="counter-reset: section 7" class="col-12">
  <!-- ReleaseHeader --><p id="publish-box">Gravitate Health FHIR Implementation Guide - Local Development build (v0.1.0). See the <a href="http://hl7.eu/fhir/ig/gravitate-health/history.html">Directory of published versions</a></p>  <!-- EndReleaseHeader -->







<ul class="nav nav-tabs">

  <li>
    <a href="Bundle-995d3971-b899-43bf-857d-98c26634796d.html">Narrative Content</a>
  </li>


  
    <li class="active">
      <a href="#">XML</a>
    </li>
  


  
    <li>
      <a href="Bundle-995d3971-b899-43bf-857d-98c26634796d.json.html">JSON</a>
    </li>
  


  
    <li>
      <a href="Bundle-995d3971-b899-43bf-857d-98c26634796d.ttl.html">TTL</a>
    </li>
  



</ul>


<a name="root"> </a>


<h2 id="root">: 995d3971-b899-43bf-857d-98c26634796d - XML Representation</h2>

<p><a href="Bundle-995d3971-b899-43bf-857d-98c26634796d.xml" no-download="true">Raw xml</a> | <a download="null" href="Bundle-995d3971-b899-43bf-857d-98c26634796d.xml">Download</a></p>

    <!-- insert intro if present -->
  



  <pre class="xml"><code><a name="l352">​</a>

&lt;<a href="http://build.fhir.org/branches/R4B//bundle.html#Bundle">Bundle</a> xmlns="http://hl7.org/fhir"&gt;
  &lt;<a href="http://build.fhir.org/branches/R4B//bundle.html#Bundle.id">id</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#id">value</a>="995d3971-b899-43bf-857d-98c26634796d"/&gt;
&lt;!--   acme irbesartan 75 mg  Norwegian  --&gt;
  &lt;<a href="http://build.fhir.org/branches/R4B//bundle.html#Bundle.meta">meta</a>&gt;
    &lt;<a href="http://build.fhir.org/branches/R4B//resource.html#Meta#Meta.versionId">versionId</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#id">value</a>="1"/&gt;
    &lt;<a href="http://build.fhir.org/branches/R4B//resource.html#Meta#Meta.lastUpdated">lastUpdated</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#instant">value</a>="2021-06-25T22:39:35.186+00:00"/&gt;
  &lt;/meta&gt;
  &lt;<a href="http://build.fhir.org/branches/R4B//bundle.html#Bundle.identifier">identifier</a>&gt;
    &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Identifier#Identifier.system">system</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#uri">value</a>="http://ema.europa.eu/fhir/identifier/documentid"/&gt;
    &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Identifier#Identifier.value">value</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="3103a561-4b54-4e02-9cd0-eceb190a0602"/&gt;
  &lt;/identifier&gt;
  &lt;<a href="http://build.fhir.org/branches/R4B//bundle.html#Bundle.type">type</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="document"/&gt;
  &lt;<a href="http://build.fhir.org/branches/R4B//bundle.html#Bundle.timestamp">timestamp</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#instant">value</a>="2021-06-25T22:39:32+00:00"/&gt;
  &lt;<a href="http://build.fhir.org/branches/R4B//bundle.html#Bundle.entry">entry</a>&gt;
    &lt;<a href="http://build.fhir.org/branches/R4B//bundle.html#Bundle.entry.fullUrl">fullUrl</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#uri">value</a>="urn:uuid:be0cf64a-79ae-427b-bd11-06e24f7798ab"/&gt;
    &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition">resource</a>&gt;
      &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition">Composition</a>&gt;
        &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.language">language</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="no"/&gt;
        &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.text">text</a>&gt;
          &lt;<a href="http://build.fhir.org/branches/R4B//narrative.html#Narrative#Narrative.status">status</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="generated"/&gt;
          &lt;div xmlns="http://www.w3.org/1999/xhtml" xml:lang="no" lang="no"&gt;&lt;p&gt;&lt;b&gt;Generated Narrative&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;status&lt;/b&gt;: final&lt;/p&gt;&lt;p&gt;&lt;b&gt;type&lt;/b&gt;: &lt;span title="Codes: {http://spor.ema.europa.eu/v1/lists/100000155531 100000155532}"&gt;PREPARATOMTALE&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;date&lt;/b&gt;: 2021-02-01&lt;/p&gt;&lt;p&gt;&lt;b&gt;author&lt;/b&gt;: &lt;span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;title&lt;/b&gt;: BARE TEST FORMÅL - Acme irbesartan 75 mg, tablets&lt;/p&gt;&lt;h3&gt;RelatesTos&lt;/h3&gt;&lt;table class="grid"&gt;&lt;tr&gt;&lt;td&gt;-&lt;/td&gt;&lt;td&gt;&lt;b&gt;Code&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;Target[x]&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;*&lt;/td&gt;&lt;td&gt;appends&lt;/td&gt;&lt;td&gt;&lt;a href="${document[n].relatesTo}"&gt;${document[n].relatesTo}&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;<a name="end-xhtml"></a>
        &lt;/text&gt;
        &lt;<a href="http://build.fhir.org/branches/R4B//binary.html#Binary">contained</a>&gt;
          &lt;<a href="http://build.fhir.org/branches/R4B//binary.html#Binary">Binary</a>&gt;
            &lt;<a href="http://build.fhir.org/branches/R4B//binary.html#Binary.id">id</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#id">value</a>="stylesheet0"/&gt;
            &lt;<a href="http://build.fhir.org/branches/R4B//binary.html#Binary.contentType">contentType</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="stylesheet/css"/&gt;
            &lt;<a href="http://build.fhir.org/branches/R4B//binary.html#Binary.data">data</a>
                  <a href="http://build.fhir.org/branches/R4B//datatypes.html#base64Binary">value</a>="<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Calibri Light";
	panose-1:2 15 3 2 2 2 4 3 2 4;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Segoe UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@SimSun";
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:"\@MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
h1
	{mso-style-link:"Heading 1 Char";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:70.85pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-70.85pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
h2
	{mso-style-link:"Heading 2 Char";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:70.85pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-70.85pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h3
	{mso-style-link:"Heading 3 Char";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:70.85pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-70.85pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h4
	{mso-style-link:"Heading 4 Char";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:70.85pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-70.85pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h5
	{mso-style-link:"Heading 5 Char";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:70.85pt;
	text-indent:-70.85pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h6
	{mso-style-link:"Heading 6 Char";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:70.85pt;
	text-indent:-70.85pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{mso-style-link:"Heading 7 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:21.25pt;
	text-indent:-21.25pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8
	{mso-style-link:"Heading 8 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:42.5pt;
	text-indent:-21.25pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoHeading9, li.MsoHeading9, div.MsoHeading9
	{mso-style-link:"Heading 9 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Calibri Light",sans-serif;}
p.MsoIndex1, li.MsoIndex1, div.MsoIndex1
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex2, li.MsoIndex2, div.MsoIndex2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:22.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex3, li.MsoIndex3, div.MsoIndex3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:33.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex4, li.MsoIndex4, div.MsoIndex4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:44.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex5, li.MsoIndex5, div.MsoIndex5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:55.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex6, li.MsoIndex6, div.MsoIndex6
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:66.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex7, li.MsoIndex7, div.MsoIndex7
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:77.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex8, li.MsoIndex8, div.MsoIndex8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:88.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex9, li.MsoIndex9, div.MsoIndex9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:99.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc1, li.MsoToc1, div.MsoToc1
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc2, li.MsoToc2, div.MsoToc2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc3, li.MsoToc3, div.MsoToc3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:22.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc4, li.MsoToc4, div.MsoToc4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:33.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc5, li.MsoToc5, div.MsoToc5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:44.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc6, li.MsoToc6, div.MsoToc6
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:55.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc7, li.MsoToc7, div.MsoToc7
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:66.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc8, li.MsoToc8, div.MsoToc8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:77.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc9, li.MsoToc9, div.MsoToc9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:88.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoNormalIndent, li.MsoNormalIndent, div.MsoNormalIndent
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoFootnoteText, li.MsoFootnoteText, div.MsoFootnoteText
	{mso-style-link:"Footnote Text Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-style-name:"Comment Text\,Car17\,Car17 Car\,Car17 Car Car\,Char13\,Char13 Car\,Char13 Car Car";
	mso-style-link:"Comment Text Char\,Car17 Char\,Car17 Car Char\,Car17 Car Car Char\,Char13 Char\,Char13 Car Char\,Char13 Car Car Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{mso-style-link:"Header Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Arial",sans-serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{mso-style-link:"Footer Char";
	margin:0in;
	line-height:13.0pt;
	font-size:8.0pt;
	font-family:"Arial",sans-serif;}
p.MsoIndexHeading, li.MsoIndexHeading, div.MsoIndexHeading
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Calibri Light",sans-serif;
	font-weight:bold;}
p.MsoCaption, li.MsoCaption, div.MsoCaption
	{mso-style-name:"Caption\,Caption 12pt\,Caption 12pt+\,Caption-FUSA\,figure";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:center;
	page-break-after:avoid;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoTof, li.MsoTof, div.MsoTof
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoEnvelopeAddress, li.MsoEnvelopeAddress, div.MsoEnvelopeAddress
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:2.0in;
	line-height:13.0pt;
	font-size:12.0pt;
	font-family:"Calibri Light",sans-serif;}
p.MsoEnvelopeReturn, li.MsoEnvelopeReturn, div.MsoEnvelopeReturn
	{margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Calibri Light",sans-serif;}
span.MsoCommentReference
	{font-family:"Times New Roman",serif;}
span.MsoPageNumber
	{font-family:"Times New Roman",serif;}
p.MsoEndnoteText, li.MsoEndnoteText, div.MsoEndnoteText
	{mso-style-link:"Endnote Text Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToa, li.MsoToa, div.MsoToa
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoMacroText, li.MsoMacroText, div.MsoMacroText
	{mso-style-link:"Macro Text Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoToaHeading, li.MsoToaHeading, div.MsoToaHeading
	{margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	line-height:13.0pt;
	font-size:12.0pt;
	font-family:"Calibri Light",sans-serif;
	font-weight:bold;}
p.MsoList, li.MsoList, div.MsoList
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListCxSpFirst, li.MsoListCxSpFirst, div.MsoListCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListCxSpMiddle, li.MsoListCxSpMiddle, div.MsoListCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListCxSpLast, li.MsoListCxSpLast, div.MsoListCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet, li.MsoListBullet, div.MsoListBullet
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBulletCxSpFirst, li.MsoListBulletCxSpFirst, div.MsoListBulletCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBulletCxSpMiddle, li.MsoListBulletCxSpMiddle, div.MsoListBulletCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBulletCxSpLast, li.MsoListBulletCxSpLast, div.MsoListBulletCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber, li.MsoListNumber, div.MsoListNumber
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumberCxSpFirst, li.MsoListNumberCxSpFirst, div.MsoListNumberCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumberCxSpMiddle, li.MsoListNumberCxSpMiddle, div.MsoListNumberCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumberCxSpLast, li.MsoListNumberCxSpLast, div.MsoListNumberCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2, li.MsoList2, div.MsoList2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2CxSpFirst, li.MsoList2CxSpFirst, div.MsoList2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2CxSpMiddle, li.MsoList2CxSpMiddle, div.MsoList2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2CxSpLast, li.MsoList2CxSpLast, div.MsoList2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3, li.MsoList3, div.MsoList3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3CxSpFirst, li.MsoList3CxSpFirst, div.MsoList3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3CxSpMiddle, li.MsoList3CxSpMiddle, div.MsoList3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3CxSpLast, li.MsoList3CxSpLast, div.MsoList3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4, li.MsoList4, div.MsoList4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4CxSpFirst, li.MsoList4CxSpFirst, div.MsoList4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4CxSpMiddle, li.MsoList4CxSpMiddle, div.MsoList4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4CxSpLast, li.MsoList4CxSpLast, div.MsoList4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5, li.MsoList5, div.MsoList5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5CxSpFirst, li.MsoList5CxSpFirst, div.MsoList5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5CxSpMiddle, li.MsoList5CxSpMiddle, div.MsoList5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5CxSpLast, li.MsoList5CxSpLast, div.MsoList5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2, li.MsoListBullet2, div.MsoListBullet2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2CxSpFirst, li.MsoListBullet2CxSpFirst, div.MsoListBullet2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2CxSpMiddle, li.MsoListBullet2CxSpMiddle, div.MsoListBullet2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2CxSpLast, li.MsoListBullet2CxSpLast, div.MsoListBullet2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3, li.MsoListBullet3, div.MsoListBullet3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3CxSpFirst, li.MsoListBullet3CxSpFirst, div.MsoListBullet3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3CxSpMiddle, li.MsoListBullet3CxSpMiddle, div.MsoListBullet3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3CxSpLast, li.MsoListBullet3CxSpLast, div.MsoListBullet3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4, li.MsoListBullet4, div.MsoListBullet4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4CxSpFirst, li.MsoListBullet4CxSpFirst, div.MsoListBullet4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4CxSpMiddle, li.MsoListBullet4CxSpMiddle, div.MsoListBullet4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4CxSpLast, li.MsoListBullet4CxSpLast, div.MsoListBullet4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5, li.MsoListBullet5, div.MsoListBullet5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5CxSpFirst, li.MsoListBullet5CxSpFirst, div.MsoListBullet5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5CxSpMiddle, li.MsoListBullet5CxSpMiddle, div.MsoListBullet5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5CxSpLast, li.MsoListBullet5CxSpLast, div.MsoListBullet5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2, li.MsoListNumber2, div.MsoListNumber2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2CxSpFirst, li.MsoListNumber2CxSpFirst, div.MsoListNumber2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2CxSpMiddle, li.MsoListNumber2CxSpMiddle, div.MsoListNumber2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2CxSpLast, li.MsoListNumber2CxSpLast, div.MsoListNumber2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3, li.MsoListNumber3, div.MsoListNumber3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3CxSpFirst, li.MsoListNumber3CxSpFirst, div.MsoListNumber3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3CxSpMiddle, li.MsoListNumber3CxSpMiddle, div.MsoListNumber3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3CxSpLast, li.MsoListNumber3CxSpLast, div.MsoListNumber3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4, li.MsoListNumber4, div.MsoListNumber4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4CxSpFirst, li.MsoListNumber4CxSpFirst, div.MsoListNumber4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4CxSpMiddle, li.MsoListNumber4CxSpMiddle, div.MsoListNumber4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4CxSpLast, li.MsoListNumber4CxSpLast, div.MsoListNumber4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5, li.MsoListNumber5, div.MsoListNumber5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5CxSpFirst, li.MsoListNumber5CxSpFirst, div.MsoListNumber5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5CxSpMiddle, li.MsoListNumber5CxSpMiddle, div.MsoListNumber5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5CxSpLast, li.MsoListNumber5CxSpLast, div.MsoListNumber5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoTitle, li.MsoTitle, div.MsoTitle
	{mso-style-link:"Title Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	line-height:13.0pt;
	font-size:16.0pt;
	font-family:"Calibri Light",sans-serif;
	font-weight:bold;}
p.MsoClosing, li.MsoClosing, div.MsoClosing
	{mso-style-link:"Closing Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:212.6pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoSignature, li.MsoSignature, div.MsoSignature
	{mso-style-link:"Signature Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:212.6pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{mso-style-link:"Body Text Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextIndent, li.MsoBodyTextIndent, div.MsoBodyTextIndent
	{mso-style-link:"Body Text Indent Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue, li.MsoListContinue, div.MsoListContinue
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinueCxSpFirst, li.MsoListContinueCxSpFirst, div.MsoListContinueCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinueCxSpMiddle, li.MsoListContinueCxSpMiddle, div.MsoListContinueCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinueCxSpLast, li.MsoListContinueCxSpLast, div.MsoListContinueCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2, li.MsoListContinue2, div.MsoListContinue2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:28.3pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2CxSpFirst, li.MsoListContinue2CxSpFirst, div.MsoListContinue2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2CxSpMiddle, li.MsoListContinue2CxSpMiddle, div.MsoListContinue2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2CxSpLast, li.MsoListContinue2CxSpLast, div.MsoListContinue2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:28.3pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3, li.MsoListContinue3, div.MsoListContinue3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:42.45pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3CxSpFirst, li.MsoListContinue3CxSpFirst, div.MsoListContinue3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3CxSpMiddle, li.MsoListContinue3CxSpMiddle, div.MsoListContinue3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3CxSpLast, li.MsoListContinue3CxSpLast, div.MsoListContinue3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:42.45pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4, li.MsoListContinue4, div.MsoListContinue4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:56.6pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4CxSpFirst, li.MsoListContinue4CxSpFirst, div.MsoListContinue4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4CxSpMiddle, li.MsoListContinue4CxSpMiddle, div.MsoListContinue4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4CxSpLast, li.MsoListContinue4CxSpLast, div.MsoListContinue4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:56.6pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5, li.MsoListContinue5, div.MsoListContinue5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:70.75pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5CxSpFirst, li.MsoListContinue5CxSpFirst, div.MsoListContinue5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5CxSpMiddle, li.MsoListContinue5CxSpMiddle, div.MsoListContinue5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5CxSpLast, li.MsoListContinue5CxSpLast, div.MsoListContinue5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:70.75pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoMessageHeader, li.MsoMessageHeader, div.MsoMessageHeader
	{mso-style-link:"Message Header Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.7pt;
	text-indent:-56.7pt;
	line-height:13.0pt;
	background:#CCCCCC;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Calibri Light",sans-serif;}
p.MsoSubtitle, li.MsoSubtitle, div.MsoSubtitle
	{mso-style-link:"Subtitle Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	line-height:13.0pt;
	font-size:12.0pt;
	font-family:"Calibri Light",sans-serif;}
p.MsoSalutation, li.MsoSalutation, div.MsoSalutation
	{mso-style-link:"Salutation Char";
	margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoDate, li.MsoDate, div.MsoDate
	{mso-style-link:"Date Char";
	margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextFirstIndent, li.MsoBodyTextFirstIndent, div.MsoBodyTextFirstIndent
	{mso-style-link:"Body Text First Indent Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-indent:10.5pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextFirstIndent2, li.MsoBodyTextFirstIndent2, div.MsoBodyTextFirstIndent2
	{mso-style-link:"Body Text First Indent 2 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	text-indent:10.5pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoNoteHeading, li.MsoNoteHeading, div.MsoNoteHeading
	{mso-style-link:"Note Heading Char";
	margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText2, li.MsoBodyText2, div.MsoBodyText2
	{mso-style-link:"Body Text 2 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	line-height:200%;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText3, li.MsoBodyText3, div.MsoBodyText3
	{mso-style-link:"Body Text 3 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	line-height:13.0pt;
	font-size:8.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextIndent2, li.MsoBodyTextIndent2, div.MsoBodyTextIndent2
	{mso-style-link:"Body Text Indent 2 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	line-height:200%;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextIndent3, li.MsoBodyTextIndent3, div.MsoBodyTextIndent3
	{mso-style-link:"Body Text Indent 3 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	line-height:13.0pt;
	font-size:8.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBlockText, li.MsoBlockText, div.MsoBlockText
	{margin-top:0in;
	margin-right:1.0in;
	margin-bottom:6.0pt;
	margin-left:1.0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
a:link, span.MsoHyperlink
	{font-family:"Times New Roman",serif;
	color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{font-family:"Times New Roman",serif;
	color:purple;
	text-decoration:underline;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{mso-style-link:"Document Map Char";
	margin:0in;
	line-height:13.0pt;
	font-size:8.0pt;
	font-family:"Segoe UI",sans-serif;}
p.MsoPlainText, li.MsoPlainText, div.MsoPlainText
	{mso-style-link:"Plain Text Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoAutoSig, li.MsoAutoSig, div.MsoAutoSig
	{mso-style-link:"E-mail Signature Char";
	margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p
	{margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
address
	{mso-style-link:"HTML Address Char";
	margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
pre
	{mso-style-link:"HTML Preformatted Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{mso-style-link:"Comment Subject Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{mso-style-link:"Balloon Text Char";
	margin:0in;
	line-height:13.0pt;
	font-size:9.0pt;
	font-family:"Times New Roman",serif;}
p.MsoNoSpacing, li.MsoNoSpacing, div.MsoNoSpacing
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoRMPane, li.MsoRMPane, div.MsoRMPane
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.5in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParagraphCxSpFirst
	{margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListParagraphCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagraphCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.5in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoQuote, li.MsoQuote, div.MsoQuote
	{mso-style-link:"Quote Char";
	margin-top:10.0pt;
	margin-right:.6in;
	margin-bottom:8.0pt;
	margin-left:.6in;
	text-align:center;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:#404040;
	font-style:italic;}
p.MsoIntenseQuote, li.MsoIntenseQuote, div.MsoIntenseQuote
	{mso-style-link:"Intense Quote Char";
	margin-top:.25in;
	margin-right:.6in;
	margin-bottom:.25in;
	margin-left:.6in;
	text-align:center;
	line-height:13.0pt;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:#5B9BD5;
	font-style:italic;}
p.MsoBibliography, li.MsoBibliography, div.MsoBibliography
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoTocHeading, li.MsoTocHeading, div.MsoTocHeading
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:16.0pt;
	font-family:"Calibri Light",sans-serif;
	font-weight:bold;}
span.Heading1Char
	{mso-style-name:"Heading 1 Char";
	mso-style-link:"Heading 1";
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
span.Heading2Char
	{mso-style-name:"Heading 2 Char";
	mso-style-link:"Heading 2";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.Heading3Char
	{mso-style-name:"Heading 3 Char";
	mso-style-link:"Heading 3";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.Heading4Char
	{mso-style-name:"Heading 4 Char";
	mso-style-link:"Heading 4";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.Heading5Char
	{mso-style-name:"Heading 5 Char";
	mso-style-link:"Heading 5";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.Heading6Char
	{mso-style-name:"Heading 6 Char";
	mso-style-link:"Heading 6";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.Heading7Char
	{mso-style-name:"Heading 7 Char";
	mso-style-link:"Heading 7";
	font-family:"Times New Roman",serif;}
span.Heading8Char
	{mso-style-name:"Heading 8 Char";
	mso-style-link:"Heading 8";
	font-family:"Times New Roman",serif;}
span.FooterChar
	{mso-style-name:"Footer Char";
	mso-style-link:Footer;
	font-family:"Arial",sans-serif;}
span.HeaderChar
	{mso-style-name:"Header Char";
	mso-style-link:Header;
	font-family:"Arial",sans-serif;}
p.MemoHeaderStyle, li.MemoHeaderStyle, div.MemoHeaderStyle
	{mso-style-name:MemoHeaderStyle;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.9pt;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-variant:small-caps;
	font-weight:bold;}
span.BodyTextChar
	{mso-style-name:"Body Text Char";
	mso-style-link:"Body Text";}
span.CommentTextChar
	{mso-style-name:"Comment Text Char\,Car17 Char\,Car17 Car Char\,Car17 Car Car Char\,Char13 Char\,Char13 Car Char\,Char13 Car Car Char";
	mso-style-link:"Comment Text\,Car17\,Car17 Car\,Car17 Car Car\,Char13\,Char13 Car\,Char13 Car Car";
	font-family:"Times New Roman",serif;}
p.EMEAEnBodyText, li.EMEAEnBodyText, div.EMEAEnBodyText
	{mso-style-name:"EMEA En Body Text";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
span.BalloonTextChar
	{mso-style-name:"Balloon Text Char";
	mso-style-link:"Balloon Text";
	font-family:SimSun;}
p.BodytextAgency, li.BodytextAgency, div.BodytextAgency
	{mso-style-name:"Body text \(Agency\)";
	mso-style-link:"Body text \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.BodytextAgencyChar
	{mso-style-name:"Body text \(Agency\) Char";
	mso-style-link:"Body text \(Agency\)";
	font-family:"Verdana",sans-serif;}
p.DraftingNotesAgency, li.DraftingNotesAgency, div.DraftingNotesAgency
	{mso-style-name:"Drafting Notes \(Agency\)";
	mso-style-link:"Drafting Notes \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Courier New";
	color:#339966;
	font-style:italic;}
span.DraftingNotesAgencyChar
	{mso-style-name:"Drafting Notes \(Agency\) Char";
	mso-style-link:"Drafting Notes \(Agency\)";
	font-family:"Courier New";
	color:#339966;
	font-style:italic;}
p.NormalAgency, li.NormalAgency, div.NormalAgency
	{mso-style-name:"Normal \(Agency\)";
	mso-style-link:"Normal \(Agency\) Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Verdana",sans-serif;}
p.TableheadingrowsAgency, li.TableheadingrowsAgency, div.TableheadingrowsAgency
	{mso-style-name:"Table heading rows \(Agency\)";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.TabletextrowsAgency, li.TabletextrowsAgency, div.TabletextrowsAgency
	{mso-style-name:"Table text rows \(Agency\)";
	margin:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.NormalAgencyChar
	{mso-style-name:"Normal \(Agency\) Char";
	mso-style-link:"Normal \(Agency\)";
	font-family:"Verdana",sans-serif;}
span.CommentSubjectChar
	{mso-style-name:"Comment Subject Char";
	mso-style-link:"Comment Subject";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.Revisjon1, li.Revisjon1, div.Revisjon1
	{mso-style-name:Revisjon1;
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.Default, li.Default, div.Default
	{mso-style-name:Default;
	margin:0in;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.Table, li.Table, div.Table
	{mso-style-name:Table;
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:141.8pt;
	text-indent:-56.7pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.TWNormal, li.TWNormal, div.TWNormal
	{mso-style-name:"TW Normal";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.Listeavsnitt1, li.Listeavsnitt1, div.Listeavsnitt1
	{mso-style-name:Listeavsnitt1;
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.5in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Listeavsnitt1CxSpFirst, li.Listeavsnitt1CxSpFirst, div.Listeavsnitt1CxSpFirst
	{mso-style-name:Listeavsnitt1CxSpFirst;
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Listeavsnitt1CxSpMiddle, li.Listeavsnitt1CxSpMiddle, div.Listeavsnitt1CxSpMiddle
	{mso-style-name:Listeavsnitt1CxSpMiddle;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Listeavsnitt1CxSpLast, li.Listeavsnitt1CxSpLast, div.Listeavsnitt1CxSpLast
	{mso-style-name:Listeavsnitt1CxSpLast;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.5in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.FootnoteTextChar
	{mso-style-name:"Footnote Text Char";
	mso-style-link:"Footnote Text";
	font-family:"Times New Roman",serif;}
p.TableFootnote, li.TableFootnote, div.TableFootnote
	{mso-style-name:"Table Footnote";
	margin:0in;
	font-size:8.0pt;
	font-family:"Arial",sans-serif;}
p.TableText, li.TableText, div.TableText
	{mso-style-name:"Table Text";
	mso-style-link:"Table Text Char";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	font-size:11.0pt;
	font-family:"Verdana",sans-serif;}
p.TableTitle, li.TableTitle, div.TableTitle
	{mso-style-name:"Table Title";
	mso-style-link:"Table Title Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:justify;
	text-justify:inter-ideograph;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.TableTextChar
	{mso-style-name:"Table Text Char";
	mso-style-link:"Table Text";
	font-family:"Verdana",sans-serif;}
span.TableTitleChar
	{mso-style-name:"Table Title Char";
	mso-style-link:"Table Title";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.Body, li.Body, div.Body
	{mso-style-name:Body;
	mso-style-link:"Body Car";
	margin-top:3.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
span.BodyCar
	{mso-style-name:"Body Car";
	mso-style-link:Body;
	font-family:"Times New Roman",serif;}
p.QRDBookmark, li.QRDBookmark, div.QRDBookmark
	{mso-style-name:"QRD Bookmark";
	margin:0in;
	text-align:center;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.BodytextEMA, li.BodytextEMA, div.BodytextEMA
	{mso-style-name:"Body text \(EMA\)";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
p.QRDBookmark2, li.QRDBookmark2, div.QRDBookmark2
	{mso-style-name:"QRD Bookmark2";
	margin:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.BodyText2Char
	{mso-style-name:"Body Text 2 Char";
	mso-style-link:"Body Text 2";}
span.BodyText3Char
	{mso-style-name:"Body Text 3 Char";
	mso-style-link:"Body Text 3";}
span.BodyTextFirstIndentChar
	{mso-style-name:"Body Text First Indent Char";
	mso-style-link:"Body Text First Indent";}
span.BodyTextIndentChar
	{mso-style-name:"Body Text Indent Char";
	mso-style-link:"Body Text Indent";}
span.BodyTextFirstIndent2Char
	{mso-style-name:"Body Text First Indent 2 Char";
	mso-style-link:"Body Text First Indent 2";}
span.BodyTextIndent2Char
	{mso-style-name:"Body Text Indent 2 Char";
	mso-style-link:"Body Text Indent 2";}
span.BodyTextIndent3Char
	{mso-style-name:"Body Text Indent 3 Char";
	mso-style-link:"Body Text Indent 3";}
span.ClosingChar
	{mso-style-name:"Closing Char";
	mso-style-link:Closing;}
span.DateChar
	{mso-style-name:"Date Char";
	mso-style-link:Date;}
span.DocumentMapChar
	{mso-style-name:"Document Map Char";
	mso-style-link:"Document Map";
	font-family:"Segoe UI",sans-serif;}
span.E-mailSignatureChar
	{mso-style-name:"E-mail Signature Char";
	mso-style-link:"E-mail Signature";}
span.EndnoteTextChar
	{mso-style-name:"Endnote Text Char";
	mso-style-link:"Endnote Text";}
span.Heading9Char
	{mso-style-name:"Heading 9 Char";
	mso-style-link:"Heading 9";
	font-family:"Calibri Light",sans-serif;}
span.HTMLAddressChar
	{mso-style-name:"HTML Address Char";
	mso-style-link:"HTML Address";
	font-style:italic;}
span.HTMLPreformattedChar
	{mso-style-name:"HTML Preformatted Char";
	mso-style-link:"HTML Preformatted";
	font-family:"Courier New";}
span.IntenseQuoteChar
	{mso-style-name:"Intense Quote Char";
	mso-style-link:"Intense Quote";
	color:#5B9BD5;
	font-style:italic;}
span.MacroTextChar
	{mso-style-name:"Macro Text Char";
	mso-style-link:"Macro Text";
	font-family:"Courier New";}
span.MessageHeaderChar
	{mso-style-name:"Message Header Char";
	mso-style-link:"Message Header";
	font-family:"Calibri Light",sans-serif;
	background:#CCCCCC;}
span.NoteHeadingChar
	{mso-style-name:"Note Heading Char";
	mso-style-link:"Note Heading";}
span.PlainTextChar
	{mso-style-name:"Plain Text Char";
	mso-style-link:"Plain Text";
	font-family:"Courier New";}
span.QuoteChar
	{mso-style-name:"Quote Char";
	mso-style-link:Quote;
	color:#404040;
	font-style:italic;}
span.SalutationChar
	{mso-style-name:"Salutation Char";
	mso-style-link:Salutation;}
span.SignatureChar
	{mso-style-name:"Signature Char";
	mso-style-link:Signature;}
span.SubtitleChar
	{mso-style-name:"Subtitle Char";
	mso-style-link:Subtitle;
	font-family:"Calibri Light",sans-serif;}
span.TitleChar
	{mso-style-name:"Title Char";
	mso-style-link:Title;
	font-family:"Calibri Light",sans-serif;
	font-weight:bold;}
p.No-numheading3Agency, li.No-numheading3Agency, div.No-numheading3Agency
	{mso-style-name:"No-num heading 3 \(Agency\)";
	mso-style-link:"No-num heading 3 \(Agency\) Char";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
span.No-numheading3AgencyChar
	{mso-style-name:"No-num heading 3 \(Agency\) Char";
	mso-style-link:"No-num heading 3 \(Agency\)";
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
 /* Page Definitions */
 @page WordSection1
	{size:595.35pt 842.0pt;
	margin:56.7pt 70.9pt 56.7pt 70.9pt;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>"/&gt;
          &lt;/Binary&gt;
        &lt;/contained&gt;
        &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.extension">extension</a>
                   <a href="http://build.fhir.org/branches/R4B//datatypes.html#uri">url</a>="http://ema.europa.eu/fhir/extension/dummyValidationReference"&gt;
          &lt;<a href="http://build.fhir.org/branches/R4B//extensibility.html#Extension#Extension.value[x]">valueReference</a>&gt;
            &lt;<a href="http://build.fhir.org/branches/R4B//references.html#Reference#Reference.reference">reference</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="#stylesheet0"/&gt;
          &lt;/valueReference&gt;
        &lt;/extension&gt;
        &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.status">status</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="final"/&gt;
        &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.type">type</a>&gt;
          &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#CodeableConcept#CodeableConcept.coding">coding</a>&gt;
            &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.system">system</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#uri">value</a>="http://spor.ema.europa.eu/v1/lists/100000155531"/&gt;
            &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.code">code</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="100000155532"/&gt;
            &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.display">display</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="PREPARATOMTALE"/&gt;
          &lt;/coding&gt;
        &lt;/type&gt;
        &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.subject">subject</a>&gt;
          &lt;<a href="http://build.fhir.org/branches/R4B//references.html#Reference#Reference.reference">reference</a>
                     <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="[http://spor.ema.europa.eu/v2/MedicinalProductDefinition]"/&gt;
          &lt;<a href="http://build.fhir.org/branches/R4B//references.html#Reference#Reference.identifier">identifier</a>&gt;
          &lt;!--  Market Authorization Number (MAN)  --&gt;
            &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Identifier#Identifier.system">system</a>
                    <a href="http://build.fhir.org/branches/R4B//datatypes.html#uri">value</a>="http://spor.ema.europa.eu/v2/marketing-authorisation-numbers"/&gt;
            &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Identifier#Identifier.value">value</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="EMEA/H/C/000142"/&gt;
          &lt;/identifier&gt;
        &lt;/subject&gt;
        &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.date">date</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#dateTime">value</a>="2021-02-01"/&gt;
        &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.author">author</a>&gt;
          &lt;<a href="http://build.fhir.org/branches/R4B//references.html#Reference#Reference.identifier">identifier</a>&gt;
            &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Identifier#Identifier.system">system</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#uri">value</a>="[http://spor.ema.europa.eu/v1/100000000005]"/&gt;
            &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Identifier#Identifier.value">value</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="2222"/&gt;
          &lt;/identifier&gt;
        &lt;/author&gt;
        &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.title">title</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="BARE TEST FORMÅL - Acme irbesartan 75 mg, tablets"/&gt;
        &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.relatesTo">relatesTo</a>&gt;
          &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.relatesTo.code">code</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="appends"/&gt;
          &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.relatesTo.target[x]">targetReference</a>&gt;
            &lt;<a href="http://build.fhir.org/branches/R4B//references.html#Reference#Reference.reference">reference</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="${document[n].relatesTo}"/&gt;
          &lt;/targetReference&gt;
        &lt;/relatesTo&gt;
        &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section">section</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#id">id</a>="dd73476d-11a5-4ca6-8cd7-398851990760"&gt;
          &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.title">title</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="PREPARATOMTALE"/&gt;
          &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.code">code</a>&gt;
            &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#CodeableConcept#CodeableConcept.coding">coding</a>&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.system">system</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#uri">value</a>="http://spor.ema.europa.eu/v1/example-sections"/&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.code">code</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="1"/&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.display">display</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="PREPARATOMTALE"/&gt;
            &lt;/coding&gt;
          &lt;/code&gt;
          &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.text">text</a>&gt;
            &lt;<a href="http://build.fhir.org/branches/R4B//narrative.html#Narrative#Narrative.status">status</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="additional"/&gt;
            &lt;div xmlns="http://www.w3.org/1999/xhtml"&gt;
                            &lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;,serif;  color:green" lang="NO-BOK"&gt;
                                &lt;br clear="all" style="page-break-before:always"/&gt;
                            &lt;/span&gt;
                            &lt;br clear="all" style="page-break-before:always"/&gt;
                        &lt;/div&gt;<a name="end-xhtml"></a>
          &lt;/text&gt;
          &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.section">section</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#id">id</a>="4af9071e-08ed-49e1-8e94-f5751e5287ed"&gt;
            &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.title">title</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="1.       LEGEMIDLETS NAVN"/&gt;
            &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.code">code</a>&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#CodeableConcept#CodeableConcept.coding">coding</a>&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.system">system</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#uri">value</a>="http://spor.ema.europa.eu/v1/example-sections"/&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.code">code</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="3"/&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.display">display</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="1. LEGEMIDLETS NAVN"/&gt;
              &lt;/coding&gt;
            &lt;/code&gt;
            &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.text">text</a>&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//narrative.html#Narrative#Narrative.status">status</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="additional"/&gt;
              &lt;div xmlns="http://www.w3.org/1999/xhtml"&gt;
                                &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"/&gt;
                                &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                    &lt;span lang="NO-BOK"&gt;Acme Product 30 mg enterotabletter&lt;/span&gt;
                                &lt;/p&gt;
                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                    &lt;span lang="NO-BOK"&gt;Acme Product 120 mg enterotabletter&lt;/span&gt;
                                &lt;/p&gt;
                                &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                            &lt;/div&gt;<a name="end-xhtml"></a>
            &lt;/text&gt;
          &lt;/section&gt;
          &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.section">section</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#id">id</a>="7f61983d-3508-46c6-96f7-f069c3c544a3"&gt;
            &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.title">title</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="2.       KVALITATIV OG KVANTITATIV SAMMENSETNING"/&gt;
            &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.code">code</a>&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#CodeableConcept#CodeableConcept.coding">coding</a>&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.system">system</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#uri">value</a>="http://spor.ema.europa.eu/v1/example-sections"/&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.code">code</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="4"/&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.display">display</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="2. KVALITATIV OG KVANTITATIV SAMMENSETNING"/&gt;
              &lt;/coding&gt;
            &lt;/code&gt;
            &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.text">text</a>&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//narrative.html#Narrative#Narrative.status">status</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="additional"/&gt;
              &lt;div xmlns="http://www.w3.org/1999/xhtml"&gt;
                                &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"/&gt;
                                &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                    &lt;u&gt;
                                        &lt;span lang="NO-BOK"&gt;Acme Product 30 mg&lt;/span&gt;
                                    &lt;/u&gt;
                                &lt;/p&gt;
                                &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                    &lt;span lang="NO-BOK"&gt;Hver enterotablett inneholder 30 mg dimetylfumarat.&lt;/span&gt;
                                &lt;/p&gt;
                                &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                    &lt;u&gt;
                                        &lt;span lang="NO-BOK"&gt;Acme Product 120 mg&lt;/span&gt;
                                    &lt;/u&gt;
                                &lt;/p&gt;
                                &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                    &lt;span lang="NO-BOK"&gt;Hver enterotablett inneholder 120 mg dimetylfumarat.&lt;/span&gt;
                                &lt;/p&gt;
                                &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                            &lt;/div&gt;<a name="end-xhtml"></a>
            &lt;/text&gt;
            &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.section">section</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#id">id</a>="07a757b3-2ee0-4b50-8501-d009425d000f"&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.title">title</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="Hjelpestoff med kjent effekt"/&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.code">code</a>&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#CodeableConcept#CodeableConcept.coding">coding</a>&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.system">system</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#uri">value</a>="http://spor.ema.europa.eu/v1/example-sections"/&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.code">code</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="7"/&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.display">display</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="Hjelpestoff(er) med kjent effekt"/&gt;
                &lt;/coding&gt;
              &lt;/code&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.text">text</a>&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//narrative.html#Narrative#Narrative.status">status</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="additional"/&gt;
                &lt;div xmlns="http://www.w3.org/1999/xhtml"&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                        &lt;u&gt;
                                            &lt;span lang="NO-BOK"&gt;Acme Product 30 mg&lt;/span&gt;
                                        &lt;/u&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                        &lt;span lang="NO-BOK"&gt;Hver enterotablett inneholder 34,2 mg laktose (som monohydrat).&lt;/span&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                        &lt;u&gt;
                                            &lt;span lang="NO-BOK"&gt;Acme Product 120 mg&lt;/span&gt;
                                        &lt;/u&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                        &lt;span lang="NO-BOK"&gt;Hver enterotablett inneholder 136,8 mg laktose (som monohydrat).&lt;/span&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                        &lt;span lang="NO-BOK"&gt;For fullstendig liste over hjelpestoffer, se pkt. 6.1.&lt;/span&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                &lt;/div&gt;<a name="end-xhtml"></a>
              &lt;/text&gt;
            &lt;/section&gt;
          &lt;/section&gt;
          &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.section">section</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#id">id</a>="4a2a8397-7ff0-4b3b-a3fd-25396bfbbf83"&gt;
            &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.title">title</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="3.       LEGEMIDDELFORM"/&gt;
            &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.code">code</a>&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#CodeableConcept#CodeableConcept.coding">coding</a>&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.system">system</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#uri">value</a>="http://spor.ema.europa.eu/v1/example-sections"/&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.code">code</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="8"/&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.display">display</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="3. LEGEMIDDELFORM"/&gt;
              &lt;/coding&gt;
            &lt;/code&gt;
            &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.text">text</a>&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//narrative.html#Narrative#Narrative.status">status</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="additional"/&gt;
              &lt;div xmlns="http://www.w3.org/1999/xhtml"&gt;
                                &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"/&gt;
                                &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                    &lt;span lang="NO-BOK"&gt;Enterotablett.&lt;/span&gt;
                                &lt;/p&gt;
                                &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                    &lt;u&gt;
                                        &lt;span lang="NO-BOK"&gt;Acme Product 30 mg&lt;/span&gt;
                                    &lt;/u&gt;
                                &lt;/p&gt;
                                &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                    &lt;span lang="NO-BOK"&gt;Hvit, filmdrasjert, rund, bikonveks tablett med en diameter på omtrent 6,8 mm. &lt;/span&gt;
                                &lt;/p&gt;
                                &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                    &lt;u&gt;
                                        &lt;span lang="NO-BOK"&gt;Acme Product 120 mg&lt;/span&gt;
                                    &lt;/u&gt;
                                &lt;/p&gt;
                                &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                    &lt;span lang="NO-BOK"&gt;Blå, filmdrasjert, rund, bikonveks tablett med en diameter på omtrent 11,6 mm. &lt;/span&gt;
                                &lt;/p&gt;
                                &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                            &lt;/div&gt;<a name="end-xhtml"></a>
            &lt;/text&gt;
          &lt;/section&gt;
          &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.section">section</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#id">id</a>="f2d48864-01c6-415a-9841-867b35715dff"&gt;
            &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.title">title</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="4.       KLINISKE OPPLYSNINGER"/&gt;
            &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.code">code</a>&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#CodeableConcept#CodeableConcept.coding">coding</a>&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.system">system</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#uri">value</a>="http://spor.ema.europa.eu/v1/example-sections"/&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.code">code</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="9"/&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.display">display</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="4. KLINISKE OPPLYSNINGER"/&gt;
              &lt;/coding&gt;
            &lt;/code&gt;
            &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.text">text</a>&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//narrative.html#Narrative#Narrative.status">status</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="additional"/&gt;
              &lt;div xmlns="http://www.w3.org/1999/xhtml"&gt;
                                &lt;p style="margin-left:28.35pt;text-indent:-28.35pt;line-height:  normal;page-break-after:avoid" class="MsoNormal"/&gt;
                            &lt;/div&gt;<a name="end-xhtml"></a>
            &lt;/text&gt;
            &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.section">section</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#id">id</a>="dc99f499-3c44-4337-aa3d-26e3d9c0d0bc"&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.title">title</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="4.1     Indikasjoner"/&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.code">code</a>&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#CodeableConcept#CodeableConcept.coding">coding</a>&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.system">system</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#uri">value</a>="http://spor.ema.europa.eu/v1/example-sections"/&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.code">code</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="10"/&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.display">display</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="4.1 Indikasjon(er)"/&gt;
                &lt;/coding&gt;
              &lt;/code&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.text">text</a>&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//narrative.html#Narrative#Narrative.status">status</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="additional"/&gt;
                &lt;div xmlns="http://www.w3.org/1999/xhtml"&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"/&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                        &lt;span lang="NO-BOK"&gt;Acme Product er indisert til behandling av moderat til alvorlig plakkpsoriasis hos voksne som har behov for systemisk medisinsk behandling. &lt;/span&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                &lt;/div&gt;<a name="end-xhtml"></a>
              &lt;/text&gt;
            &lt;/section&gt;
            &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.section">section</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#id">id</a>="fd5ee14d-0a47-4a6e-89a3-a22fc6e1a614"&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.title">title</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="4.2     Dosering og administrasjonsmåte"/&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.code">code</a>&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#CodeableConcept#CodeableConcept.coding">coding</a>&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.system">system</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#uri">value</a>="http://spor.ema.europa.eu/v1/example-sections"/&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.code">code</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="11"/&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.display">display</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="4.2 Dosering og administrasjonsmåte"/&gt;
                &lt;/coding&gt;
              &lt;/code&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.text">text</a>&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//narrative.html#Narrative#Narrative.status">status</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="additional"/&gt;
                &lt;div xmlns="http://www.w3.org/1999/xhtml"&gt;
                                    &lt;p style="margin-left:28.35pt;text-indent:-28.35pt;line-height:  normal;page-break-after:avoid" class="MsoNormal"/&gt;
                                    &lt;p style="text-indent:-1.35pt;line-height:normal;page-break-after:  avoid" class="MsoNormal"&gt;
                                        &lt;span lang="NO-BOK"&gt;Acme Product er beregnet til bruk under veiledning og tilsyn av en lege som har erfaring innen diagnostisering og behandling av psoriasis.&lt;/span&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                        &lt;u&gt;
                                            &lt;span lang="NO-BOK"/&gt;
                                        &lt;/u&gt;
                                    &lt;/p&gt;
                                &lt;/div&gt;<a name="end-xhtml"></a>
              &lt;/text&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.section">section</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#id">id</a>="80703ee9-c748-429d-bcb8-c3d84f8ebc3c"&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.title">title</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="Dosering"/&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.code">code</a>&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#CodeableConcept#CodeableConcept.coding">coding</a>&gt;
                    &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.system">system</a>
                            <a href="http://build.fhir.org/branches/R4B//datatypes.html#uri">value</a>="http://spor.ema.europa.eu/v1/example-sections"/&gt;
                    &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.code">code</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="12"/&gt;
                    &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.display">display</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="Dosering"/&gt;
                  &lt;/coding&gt;
                &lt;/code&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.text">text</a>&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//narrative.html#Narrative#Narrative.status">status</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="additional"/&gt;
                  &lt;div xmlns="http://www.w3.org/1999/xhtml"&gt;
                                        &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                            &lt;span lang="NO-BOK"&gt;For å bedre toleransen anbefales det å begynne behandlingen med en lav startdose med gradvis økning. I den første uken skal Acme Product 30 mg tas én gang daglig (1 tablett om kvelden). I den andre uken skal Acme Product 30 mg tas to ganger daglig (1 tablett om morgenen og 1 om kvelden). I den tredje uken skal Acme Product 30 mg tas tre ganger daglig (1 tablett om morgenen, 1 midt på dagen, og 1 om kvelden). Fra den fjerde uken skal behandlingen endres til bare 1 Acme Product 120 mg tablett om kvelden. Denne dosen økes deretter med 1 Acme Product 120 mg tablett per uke på ulike tider av døgnet i de neste 5 ukene, som vist i tabellen nedenfor. Maksimal tillatt daglig dose er 720 mg (3 x 2 tabletter Acme Product 120 mg).&lt;/span&gt;
                                        &lt;/p&gt;
                                        &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                        &lt;table border="0" cellpadding="0" cellspacing="0" width="100%" style="width:100.0%;border-collapse:collapse" class="MsoNormalTable"&gt;
                                            &lt;tr&gt;
                                                &lt;td width="10%" style="width:10.42%;border:solid windowtext 1.0pt;    border-bottom:none;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                                        &lt;b&gt;
                                                            &lt;span lang="NO-BOK"&gt;Uke&lt;/span&gt;
                                                        &lt;/b&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td colspan="3" width="62%" style="width:62.5%;border:solid windowtext 1.0pt;    border-left:none;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"&gt;
                                                        &lt;b&gt;
                                                            &lt;span lang="NO-BOK"&gt;Antall tabletter&lt;/span&gt;
                                                        &lt;/b&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td width="27%" style="width:27.08%;border-top:solid windowtext 1.0pt;    border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"&gt;
                                                        &lt;b&gt;
                                                            &lt;span lang="NO-BOK"&gt;Total daglig dose (mg)&lt;/span&gt;
                                                        &lt;/b&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td width="10%" style="width:10.42%;border:solid windowtext 1.0pt;    border-top:none;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"/&gt;
                                                &lt;/td&gt;
                                                &lt;td width="20%" style="width:20.84%;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"&gt;
                                                        &lt;b&gt;
                                                            &lt;span lang="NO-BOK"&gt;Morgen&lt;/span&gt;
                                                        &lt;/b&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td width="20%" style="width:20.84%;border:solid windowtext 1.0pt;    border-left:none;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"&gt;
                                                        &lt;b&gt;
                                                            &lt;span lang="NO-BOK"&gt;Midt på dagen&lt;/span&gt;
                                                        &lt;/b&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td width="20%" style="width:20.84%;border:solid windowtext 1.0pt;    border-left:none;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"&gt;
                                                        &lt;b&gt;
                                                            &lt;span lang="NO-BOK"&gt;Kveld&lt;/span&gt;
                                                        &lt;/b&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td width="27%" style="width:27.08%;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"&gt;
                                                        &lt;b&gt;
                                                            &lt;span lang="NO-BOK"&gt;med dimetylfumarat &lt;/span&gt;
                                                        &lt;/b&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td colspan="4" width="72%" style="width:72.92%;border-top:none;    border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;    border-right:none;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"&gt;
                                                        &lt;b&gt;
                                                            &lt;span lang="NO-BOK"&gt;Acme Product 30 mg&lt;/span&gt;
                                                        &lt;/b&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td width="27%" style="width:27.08%;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"/&gt;
                                                &lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td width="10%" style="width:10.42%;border-top:none;border-left:solid windowtext 1.0pt;    border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt"&gt;
                                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                                        &lt;span lang="NO-BOK"&gt;1&lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td width="20%" style="width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"&gt;
                                                        &lt;span lang="NO-BOK"&gt;0&lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td width="20%" style="width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"&gt;
                                                        &lt;span lang="NO-BOK"&gt;0&lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td width="20%" style="width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"&gt;
                                                        &lt;span lang="NO-BOK"&gt;1&lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td width="27%" style="width:27.08%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"&gt;
                                                        &lt;span lang="NO-BOK"&gt;30&lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td width="10%" style="width:10.42%;border-top:none;border-left:solid windowtext 1.0pt;    border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt"&gt;
                                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                                        &lt;span lang="NO-BOK"&gt;2&lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td width="20%" style="width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"&gt;
                                                        &lt;span lang="NO-BOK"&gt;1&lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td width="20%" style="width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"&gt;
                                                        &lt;span lang="NO-BOK"&gt;0&lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td width="20%" style="width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"&gt;
                                                        &lt;span lang="NO-BOK"&gt;1&lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td width="27%" style="width:27.08%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"&gt;
                                                        &lt;span lang="NO-BOK"&gt;60&lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td width="10%" style="width:10.42%;border:solid windowtext 1.0pt;border-top:    none;padding:1.4pt 5.4pt 1.4pt 5.4pt"&gt;
                                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                                        &lt;span lang="NO-BOK"&gt;3&lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td width="20%" style="width:20.84%;border-top:none;border-left:none;    border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"&gt;
                                                        &lt;span lang="NO-BOK"&gt;1&lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td width="20%" style="width:20.84%;border-top:none;border-left:none;    border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"&gt;
                                                        &lt;span lang="NO-BOK"&gt;1&lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td width="20%" style="width:20.84%;border-top:none;border-left:none;    border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"&gt;
                                                        &lt;span lang="NO-BOK"&gt;1&lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td width="27%" style="width:27.08%;border-top:none;border-left:none;    border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"&gt;
                                                        &lt;span lang="NO-BOK"&gt;90&lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td colspan="4" width="72%" style="width:72.92%;border-top:none;border-left:    solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:    none;padding:1.4pt 5.4pt 1.4pt 5.4pt"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"&gt;
                                                        &lt;b&gt;
                                                            &lt;span lang="NO-BOK"&gt;Acme Product 120 mg&lt;/span&gt;
                                                        &lt;/b&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td width="27%" style="width:27.08%;border-top:none;border-left:none;    border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"/&gt;
                                                &lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr style="height:11.55pt"&gt;
                                                &lt;td width="10%" style="width:10.42%;border-top:none;border-left:solid windowtext 1.0pt;    border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt;    height:11.55pt"&gt;
                                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                                        &lt;span lang="NO-BOK"&gt;4&lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td width="20%" style="width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:11.55pt"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"&gt;
                                                        &lt;span lang="NO-BOK"&gt;0&lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td width="20%" style="width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:11.55pt"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"&gt;
                                                        &lt;span lang="NO-BOK"&gt;0&lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td width="20%" style="width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:11.55pt"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"&gt;
                                                        &lt;span lang="NO-BOK"&gt;1&lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td width="27%" style="width:27.08%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:11.55pt"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"&gt;
                                                        &lt;span lang="NO-BOK"&gt;120&lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr style="height:12.65pt"&gt;
                                                &lt;td width="10%" style="width:10.42%;border-top:none;border-left:solid windowtext 1.0pt;    border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt;    height:12.65pt"&gt;
                                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                                        &lt;span lang="NO-BOK"&gt;5&lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td width="20%" style="width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:12.65pt"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"&gt;
                                                        &lt;span lang="NO-BOK"&gt;1&lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td width="20%" style="width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:12.65pt"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"&gt;
                                                        &lt;span lang="NO-BOK"&gt;0&lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td width="20%" style="width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:12.65pt"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"&gt;
                                                        &lt;span lang="NO-BOK"&gt;1&lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td width="27%" style="width:27.08%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:12.65pt"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"&gt;
                                                        &lt;span lang="NO-BOK"&gt;240&lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr style="height:16.15pt"&gt;
                                                &lt;td width="10%" style="width:10.42%;border-top:none;border-left:solid windowtext 1.0pt;    border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt;    height:16.15pt"&gt;
                                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                                        &lt;span lang="NO-BOK"&gt;6&lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td width="20%" style="width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:16.15pt"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"&gt;
                                                        &lt;span lang="NO-BOK"&gt;1&lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td width="20%" style="width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:16.15pt"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"&gt;
                                                        &lt;span lang="NO-BOK"&gt;1&lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td width="20%" style="width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:16.15pt"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"&gt;
                                                        &lt;span lang="NO-BOK"&gt;1&lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td width="27%" style="width:27.08%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:16.15pt"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"&gt;
                                                        &lt;span lang="NO-BOK"&gt;360&lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr style="height:12.1pt"&gt;
                                                &lt;td width="10%" style="width:10.42%;border-top:none;border-left:solid windowtext 1.0pt;    border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt;    height:12.1pt"&gt;
                                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                                        &lt;span lang="NO-BOK"&gt;7&lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td width="20%" style="width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:12.1pt"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"&gt;
                                                        &lt;span lang="NO-BOK"&gt;1&lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td width="20%" style="width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:12.1pt"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"&gt;
                                                        &lt;span lang="NO-BOK"&gt;1&lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td width="20%" style="width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:12.1pt"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"&gt;
                                                        &lt;span lang="NO-BOK"&gt;2&lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td width="27%" style="width:27.08%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:12.1pt"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"&gt;
                                                        &lt;span lang="NO-BOK"&gt;480&lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr style="height:13.25pt"&gt;
                                                &lt;td width="10%" style="width:10.42%;border-top:none;border-left:solid windowtext 1.0pt;    border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt;    height:13.25pt"&gt;
                                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                                        &lt;span lang="NO-BOK"&gt;8&lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td width="20%" style="width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:13.25pt"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"&gt;
                                                        &lt;span lang="NO-BOK"&gt;2&lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td width="20%" style="width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:13.25pt"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"&gt;
                                                        &lt;span lang="NO-BOK"&gt;1&lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td width="20%" style="width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:13.25pt"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"&gt;
                                                        &lt;span lang="NO-BOK"&gt;2&lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td width="27%" style="width:27.08%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:13.25pt"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"&gt;
                                                        &lt;span lang="NO-BOK"&gt;600&lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr style="height:15.85pt"&gt;
                                                &lt;td width="10%" style="width:10.42%;border:solid windowtext 1.0pt;border-top:    none;padding:1.4pt 5.4pt 1.4pt 5.4pt;height:15.85pt"&gt;
                                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                                        &lt;span lang="NO-BOK"&gt;9+&lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td width="20%" style="width:20.84%;border-top:none;border-left:none;    border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:15.85pt"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"&gt;
                                                        &lt;span lang="NO-BOK"&gt;2&lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td width="20%" style="width:20.84%;border-top:none;border-left:none;    border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:15.85pt"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"&gt;
                                                        &lt;span lang="NO-BOK"&gt;2&lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td width="20%" style="width:20.84%;border-top:none;border-left:none;    border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:15.85pt"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"&gt;
                                                        &lt;span lang="NO-BOK"&gt;2&lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td width="27%" style="width:27.08%;border-top:none;border-left:none;    border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:15.85pt"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"&gt;
                                                        &lt;span lang="NO-BOK"&gt;720&lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                            &lt;/tr&gt;
                                        &lt;/table&gt;
                                        &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                        &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                            &lt;span lang="NO-BOK"&gt;Hvis en bestemt dose ikke tolereres, kan den midlertidig reduseres til sist tolererte dose.&lt;/span&gt;
                                        &lt;/p&gt;
                                        &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                        &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                            &lt;span lang="NO-BOK"&gt;Hvis behandlingseffekt observeres før maksimaldosen er nådd, er det ikke nødvendig med ytterligere økning av dosen. Etter at en klinisk relevant forbedring av hudlesjoner er oppnådd, skal det vurderes en gradvis reduksjon av den daglige dosen av Acme Product til vedlikeholdsdosen som kreves hos den enkelte person.&lt;/span&gt;
                                        &lt;/p&gt;
                                        &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                        &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                            &lt;span lang="NO-BOK"&gt;Doseringsmodifikasjoner kan også være nødvendig ved observasjon av unormale laboratorieparametre (se pkt. 4.4).&lt;/span&gt;
                                        &lt;/p&gt;
                                        &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                        &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                            &lt;i&gt;
                                                &lt;span lang="NO-BOK"&gt;Eldre pasienter&lt;/span&gt;
                                            &lt;/i&gt;
                                        &lt;/p&gt;
                                        &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                            &lt;span lang="NO-BOK"&gt;Kliniske studier av Acme Product inkluderte ikke et tilstrekkelig antall pasienter i alderen 65 år og over for å kunne avgjøre hvorvidt de responderer annerledes sammenlignet med pasienter under 65 år (se pkt. 5.2). Basert på farmakologien til dimetylfumarat, &lt;/span&gt;
                                            &lt;span lang="NO-BOK"&gt;er&lt;/span&gt;
                                            &lt;span lang="NO-BOK"&gt;et behov for justering av dosen hos eldre&lt;/span&gt;
                                            &lt;span lang="NO-BOK"&gt;ikke forventet&lt;/span&gt;
                                            &lt;span lang="NO-BOK"&gt;.&lt;/span&gt;
                                        &lt;/p&gt;
                                        &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                        &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                            &lt;i&gt;
                                                &lt;span lang="NO-BOK"&gt;Nedsatt nyrefunksjon&lt;/span&gt;
                                            &lt;/i&gt;
                                        &lt;/p&gt;
                                        &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                            &lt;span lang="NO-BOK"&gt;Ingen dosejustering er nødvendig hos pasienter med mild til moderat nedsatt nyrefunksjon (se pkt. 5.2). Acme Product er ikke undersøkt hos pasienter med alvorlig nedsatt nyrefunksjon, og bruk av Acme Product er kontraindisert hos disse pasientene (se pkt. 4.3).&lt;/span&gt;
                                        &lt;/p&gt;
                                        &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                        &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                            &lt;i&gt;
                                                &lt;span lang="NO-BOK"&gt;Nedsatt leverfunksjon&lt;/span&gt;
                                            &lt;/i&gt;
                                        &lt;/p&gt;
                                        &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                            &lt;span lang="NO-BOK"&gt;Ingen dosejustering er nødvendig hos pasienter med mild til moderat nedsatt leverfunksjon (se pkt. 5.2). Acme Product er ikke undersøkt hos pasienter med alvorlig nedsatt leverfunksjon, og bruken av Acme Product er kontraindisert hos disse pasientene (se pkt. 4.3).&lt;/span&gt;
                                        &lt;/p&gt;
                                        &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                    &lt;/div&gt;<a name="end-xhtml"></a>
                &lt;/text&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.section">section</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#id">id</a>="c9f25cf2-76f8-4f46-9e79-df85bb5185ed"&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.title">title</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="Pediatrisk populasjon"/&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.code">code</a>&gt;
                    &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#CodeableConcept#CodeableConcept.coding">coding</a>&gt;
                      &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.system">system</a>
                              <a href="http://build.fhir.org/branches/R4B//datatypes.html#uri">value</a>="http://spor.ema.europa.eu/v1/example-sections"/&gt;
                      &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.code">code</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="13"/&gt;
                      &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.display">display</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="Pediatrisk populasjon"/&gt;
                    &lt;/coding&gt;
                  &lt;/code&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.text">text</a>&gt;
                    &lt;<a href="http://build.fhir.org/branches/R4B//narrative.html#Narrative#Narrative.status">status</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="additional"/&gt;
                    &lt;div xmlns="http://www.w3.org/1999/xhtml"&gt;
                                            &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                                &lt;span lang="NO-BOK"&gt;Sikkerhet og effekt av Acme Product hos den pediatriske populasjonen under en alder på 18 år har ikke blitt fastslått. Det finnes ingen tilgjengelige data for Acme Product hos den pediatriske populasjonen.&lt;/span&gt;
                                            &lt;/p&gt;
                                            &lt;p style="line-height:normal;text-autospace:none" class="MsoNormal"/&gt;
                                        &lt;/div&gt;<a name="end-xhtml"></a>
                  &lt;/text&gt;
                &lt;/section&gt;
              &lt;/section&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.section">section</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#id">id</a>="82cfd9b0-45eb-46d7-921b-57ff3afd01c9"&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.title">title</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="Administrasjonsmåte"/&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.code">code</a>&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#CodeableConcept#CodeableConcept.coding">coding</a>&gt;
                    &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.system">system</a>
                            <a href="http://build.fhir.org/branches/R4B//datatypes.html#uri">value</a>="http://spor.ema.europa.eu/v1/example-sections"/&gt;
                    &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.code">code</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="14"/&gt;
                    &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.display">display</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="Administrasjonsmåte"/&gt;
                  &lt;/coding&gt;
                &lt;/code&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.text">text</a>&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//narrative.html#Narrative#Narrative.status">status</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="additional"/&gt;
                  &lt;div xmlns="http://www.w3.org/1999/xhtml"&gt;
                                        &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                            &lt;span lang="NO-BOK"&gt;Acme Product er til oral bruk. Acme Product-tablettene skal svelges hele med væske under eller rett etter et måltid.&lt;/span&gt;
                                        &lt;/p&gt;
                                        &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                            &lt;u&gt;
                                                &lt;span lang="NO-BOK"/&gt;
                                            &lt;/u&gt;
                                        &lt;/p&gt;
                                        &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                            &lt;span lang="NO-BOK"&gt;Drasjeringen på enterotablettene er designet til å forhindre mageirritasjon. Derfor skal tablettene ikke knuses, deles, oppløses eller tygges. &lt;/span&gt;
                                        &lt;/p&gt;
                                        &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                    &lt;/div&gt;<a name="end-xhtml"></a>
                &lt;/text&gt;
              &lt;/section&gt;
            &lt;/section&gt;
            &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.section">section</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#id">id</a>="c7ff6012-3955-41e9-829f-03258aec52c3"&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.title">title</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="4.3     Kontraindikasjoner"/&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.code">code</a>&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#CodeableConcept#CodeableConcept.coding">coding</a>&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.system">system</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#uri">value</a>="http://spor.ema.europa.eu/v1/example-sections"/&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.code">code</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="16"/&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.display">display</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="4.3 Kontraindikasjoner"/&gt;
                &lt;/coding&gt;
              &lt;/code&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.text">text</a>&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//narrative.html#Narrative#Narrative.status">status</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="additional"/&gt;
                &lt;div xmlns="http://www.w3.org/1999/xhtml"&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"/&gt;
                                    &lt;p style="margin-top:0in;margin-right:0in;margin-bottom:  0in;margin-left:28.35pt;text-indent:-28.35pt;page-break-after:avoid" class="Listeavsnitt1"&gt;
                                        &lt;span style="font-size:11.0pt;font-family:Symbol" lang="NO-BOK"&gt;-&lt;/span&gt;
                                        &lt;span style="font-size:11.0pt" lang="NO-BOK"&gt;Overfølsomhet overfor virkestoffet eller overfor noen av hjelpestoffene listet opp i pkt. 6.1. &lt;/span&gt;
                                    &lt;/p&gt;
                                    &lt;p style="margin-top:0in;margin-right:0in;margin-bottom:  0in;margin-left:28.35pt;text-indent:-28.35pt" class="Listeavsnitt1"&gt;
                                        &lt;span style="font-size:11.0pt;font-family:Symbol" lang="NO-BOK"&gt;-&lt;/span&gt;
                                        &lt;span style="font-size:11.0pt" lang="NO-BOK"&gt;Alvorlige gastrointestinale sykdommer.&lt;/span&gt;
                                    &lt;/p&gt;
                                    &lt;p style="margin-top:0in;margin-right:0in;margin-bottom:  0in;margin-left:28.35pt;text-indent:-28.35pt" class="Listeavsnitt1"&gt;
                                        &lt;span style="font-size:11.0pt;font-family:Symbol" lang="NO-BOK"&gt;-&lt;/span&gt;
                                        &lt;span style="font-size:11.0pt" lang="NO-BOK"&gt;Alvorlig nedsatt lever- eller nyrefunksjon.&lt;/span&gt;
                                    &lt;/p&gt;
                                    &lt;p style="margin-top:0in;margin-right:0in;margin-bottom:  0in;margin-left:28.35pt;text-indent:-28.35pt" class="Listeavsnitt1"&gt;
                                        &lt;span style="font-size:11.0pt;font-family:Symbol" lang="NO-BOK"&gt;-&lt;/span&gt;
                                        &lt;span style="font-size:11.0pt" lang="NO-BOK"&gt;Graviditet og amming.&lt;/span&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                &lt;/div&gt;<a name="end-xhtml"></a>
              &lt;/text&gt;
            &lt;/section&gt;
            &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.section">section</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#id">id</a>="590abf58-3378-437f-9015-57675c2a6b60"&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.title">title</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="4.4     Advarsler og forsiktighetsregler"/&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.code">code</a>&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#CodeableConcept#CodeableConcept.coding">coding</a>&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.system">system</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#uri">value</a>="http://spor.ema.europa.eu/v1/example-sections"/&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.code">code</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="17"/&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.display">display</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="4.4 Advarsler og forsiktighetsregler"/&gt;
                &lt;/coding&gt;
              &lt;/code&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.text">text</a>&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//narrative.html#Narrative#Narrative.status">status</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="additional"/&gt;
                &lt;div xmlns="http://www.w3.org/1999/xhtml"&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                        &lt;u&gt;
                                            &lt;span lang="NO-BOK"/&gt;
                                        &lt;/u&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                        &lt;u&gt;
                                            &lt;span lang="NO-BOK"&gt;Hematologi&lt;/span&gt;
                                        &lt;/u&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                        &lt;span lang="NO-BOK"&gt;Acme Product kan redusere antall leukocytter og lymfocytter (se pkt. 4.8). Det har ikke blitt undersøkt hos pasienter med underliggende lavt leukocytt- eller lymfocyttall.&lt;/span&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                        &lt;i&gt;
                                            &lt;span lang="NO-BOK"&gt;Før &lt;/span&gt;
                                        &lt;/i&gt;
                                        &lt;i&gt;
                                            &lt;span lang="NO-BOK"&gt;behandling&lt;/span&gt;
                                        &lt;/i&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                        &lt;span lang="NO-BOK"&gt;Før oppstart av behandling med Acme Product, bør en ny &lt;/span&gt;
                                        &lt;span lang="NO-BOK"&gt;fullstendig blodtelling&lt;/span&gt;
                                        &lt;span lang="NO-BOK"&gt;(herunder
differensialtelling og blodplater) være tilgjengelig. Behandlingen skal ikke
initieres hvis leukopeni under 3,0 x 10
                                            &lt;sup&gt;9&lt;/sup&gt;/l, lymfopeni under 1,0 x 10
                                            &lt;sup&gt;9&lt;/sup&gt;/l
eller andre patologiske resultater identifiseres.
                                        &lt;/span&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                        &lt;i&gt;
                                            &lt;span lang="NO-BOK"&gt;Under behandling&lt;/span&gt;
                                        &lt;/i&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                        &lt;span lang="NO-BOK"&gt;Under behandling skal en fullstendig blodtelling med differensialtelling utføres hver 3. måned. Det kreves tiltak ved følgende forhold:&lt;/span&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                    &lt;p style="line-height:normal" id="bffaa942-5ceb-40b6-9e61-5ff98c72b82a" class="MsoNormal"/&gt;
                                    &lt;i&gt;
                                        &lt;span lang="NO-BOK"&gt;Leukopeni:&lt;/span&gt;
                                    &lt;/i&gt;
                                    &lt;none/&gt;
                                    &lt;p style="line-height:normal" id="bffaa942-5ceb-40b6-9e61-5ff98c72b82a" class="MsoNormal"&gt;
                                        &lt;span lang="NO-BOK"&gt;Hvis det blir funnet en markert nedgang i totalt antallleukocytter, bør situasjonen overvåkes nøye og behandling med Acme Product bør avbrytesved nivåer under 3,0 x 10
                                            &lt;sup&gt;9&lt;/sup&gt;/l.
                                        &lt;/span&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                    &lt;p style="line-height:normal" id="4c859ed4-dc2a-460d-bd1e-11830edbfffa" class="MsoNormal"/&gt;
                                    &lt;i&gt;
                                        &lt;span lang="NO-BOK"&gt;Lymfopeni:&lt;/span&gt;
                                    &lt;/i&gt;
                                    &lt;none/&gt;
                                    &lt;p style="line-height:normal" id="4c859ed4-dc2a-460d-bd1e-11830edbfffa" class="MsoNormal"&gt;
                                        &lt;span lang="NO-BOK"&gt;Hvis lymfocyttnivået faller under 1,0 x 10
                                            &lt;sup&gt;9&lt;/sup&gt;/l, men er≥ 0,7 x 10
                                            &lt;sup&gt;9&lt;/sup&gt;/l, skal blodovervåkning utføres månedlig inntilnivåer returnerer til 1,0 x 10
                                            &lt;sup&gt;9&lt;/sup&gt;/l eller høyere ved to påfølgendeblodprøver, og fra dette tidspunktet kan overvåkningen igjen utføres hver 3.måned.
                                        &lt;/span&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                        &lt;span lang="NO-BOK"&gt;Hvis
lymfocyttnivået faller under 0,7 x 10
                                            &lt;sup&gt;9&lt;/sup&gt;/l, må blodprøven gjentas, og
hvis nivåene bekreftes å være under 0,7 x 10
                                            &lt;sup&gt;9&lt;/sup&gt;, må behandlingen
stoppes umiddelbart.
                                        &lt;/span&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                        &lt;span lang="NO-BOK"&gt;Pasienter som utvikler lymfopeni, skal overvåkes etter å ha avsluttet behandlingen inntil lymfocyttnivået har gått tilbake til normalområdet (se pkt. 4.8).&lt;/span&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                        &lt;i&gt;
                                            &lt;span lang="NO-BOK"&gt;Andre hematologiske sykdommer&lt;/span&gt;
                                        &lt;/i&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                        &lt;span lang="NO-BOK"&gt;Behandlingen skal avbrytes og det anbefales å utvise forsiktighet hvis andre patologiske resultater forekommer. I alle fall skal blodnivåene overvåkes inntil verdiene har gått tilbake til normalområdet.&lt;/span&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                        &lt;u&gt;
                                            &lt;span lang="NO-BOK"&gt;Infeksjoner&lt;/span&gt;
                                        &lt;/u&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                        &lt;span lang="NO-BOK"&gt;Acme Product er en immunmodulator og kan påvirke hvordan immunsystemet reagerer på infeksjoner. For pasienter med eksisterende infeksjoner av klinisk relevans, skal legen avgjøre om behandling med Acme Product først skal initieres når infeksjonen er over. Hvis en pasient utvikler en infeksjon under behandlingen med Acme Product, skal en utsettelse av behandlingen vurderes, og fordelene og risikoene skal revurderes før behandlingen påbegynnes på nytt. Pasienter som mottar Acme Product skal instrueres til å rapportere symptomer på infeksjon til en lege.&lt;/span&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                        &lt;i&gt;
                                            &lt;span lang="NO-BOK"&gt;Opportunistiske infeksjoner / progressiv multifokal leukoencefalopati (PML)&lt;/span&gt;
                                        &lt;/i&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                        &lt;span lang="NO-BOK"&gt;Tilfeller av opportunistiske infeksjoner, spesielt progressiv multifokal leukoencefalopati (PML) har blitt rapporter med andre dimetylfumaratholdige legemidler (se pkt. 4.8). PML er en opportunistisk infeksjon forårsaket av John-Cunningham-virus (JCV) som kan være dødelig eller forårsake alvorlige funksjonshemminger. PML er sannsynligvis forårsaket av en kombinasjon av faktorer.&lt;/span&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                        &lt;span lang="NO-BOK"&gt;En tidligere infeksjon med JCV anses som en forutsetning for utvikling av PML. Risikofaktorer kan inkludere tidligere immunsuppressiv behandling og eksistensen av visse samtidige sykdommer (slik som autoimmune sykdommer eller ondartede hematologiske tilstander). Et modifisert eller svekket immunsystem, samt genetiske eller miljømessige faktorer kan også utgjøre risikofaktorer.&lt;/span&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                        &lt;span lang="NO-BOK"&gt;Vedvarende moderat eller alvorlig lymfopeni i løpet av behandling med dimetylfumarat anses også som en risikofaktor for PML. Pasienter som utvikler lymfopeni skal overvåkes for tegn og symptomer på opportunistiske infeksjoner, spesielt symptomer som tyder på PML. Typiske symptomer assosiert med PML er mangfoldige, blir verre over dager til uker og inkluderer progressiv svakhet på én side av kroppen eller klumsethet i lemmene, synsforstyrrelse og endringer i tankegang, minne og orientering, noe som fører til forvirring og personlighetsforandringer. Hvis det mistenkes PML, skal behandlingen med Acme Product stoppes umiddelbart og ytterligere egnede nevrologiske og radiologiske undersøkelser gjennomføres.&lt;/span&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                        &lt;u&gt;
                                            &lt;span lang="NO-BOK"&gt;Tidligere og samtidig behandling med immunsuppressive eller immunmodulerende behandlinger&lt;/span&gt;
                                        &lt;/u&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                        &lt;span lang="NO-BOK"&gt;Det finnes begrensede data tilgjengelig om effekten og sikkerheten til Acme Product hos pasienter som tidligere har blitt behandlet med immunsuppressive eller immunmodulerende behandlinger. Når pasienter bytter fra slike behandlinger til Acme Product, skal halveringstiden og virkemåten til den andre behandlingen vurderes for å unngå additive virkninger på immunsystemet.&lt;/span&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                        &lt;span lang="NO-BOK"&gt;Det finnes ingen tilgjengelige data om effekten og sikkerheten til Acme Product når det tas samtidig med andre immunsuppressive eller immunmodulerende behandlinger (se pkt. 4.5).&lt;/span&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                        &lt;u&gt;
                                            &lt;span lang="NO-BOK"&gt;Eksisterende gastrointestinal sykdom&lt;/span&gt;
                                        &lt;/u&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                        &lt;span lang="NO-BOK"&gt;Acme Product har ikke blitt studert hos pasienter med eksisterende gastrointestinal sykdom. Acme Product er kontraindisert hos pasienter med alvorlig gastrointestinal sykdom (se pkt. 4.3). Gastrointestinal toleranse kan forbedres ved å følge dosetitreringsplanen ved oppstart av Acme Product-behandlingen og ved å ta Acme Product med mat (se pkt. 4.2 og 4.8).&lt;/span&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                        &lt;u&gt;
                                            &lt;span lang="NO-BOK"&gt;Nyrefunksjon&lt;/span&gt;
                                        &lt;/u&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                        &lt;span lang="NO-BOK"&gt;Siden eliminasjon via nyrene spiller en mindre rolle i Acme Products plasmaclearance, er det lite sannsynlig at nedsatt nyrefunksjon ville innvirke på de farmakokinetiske egenskapene, og det forventes derfor at en dosejustering ikke er nødvendig for pasienter med mild til moderat nedsatt nyrefunksjon (se pkt. 4.2 og 5.2). &lt;/span&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                        &lt;span lang="NO-BOK"&gt;I løpet av den placebokontrollerte, kliniske fase III-studien ble det ikke observert noen svekking av nyrefunksjon under behandling på tvers av behandlingsgruppene. Acme Product har imidlertid ikke blitt undersøkt hos pasienter med alvorlig nedsatt nyrefunksjon, og noen tilfeller av nyretoksisitet har blitt rapportert under overvåkning etter markedsføring med fumarsyreestere. Dermed er Acme Product kontraindisert hos pasienter med alvorlig nedsatt nyrefunksjon (se pkt. 4.3). &lt;/span&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                        &lt;span lang="NO-BOK"&gt;Nyrefunksjon (f.eks. kreatinin, blodureanitrogen og urinanalyse) skal sjekkes før behandlingsstart og hver 3. måned deretter. I tilfelle av en klinisk relevant endring i nyrefunksjon, spesielt i fravær av alternative forklaringer, bør dosereduksjon eller behandlingsseponering vurderes. &lt;/span&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                        &lt;i&gt;
                                            &lt;span lang="NO-BOK"&gt;Fanconi-syndrom&lt;/span&gt;
                                        &lt;/i&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                        &lt;span lang="NO-BOK"&gt;Tidlig diagnostisering av Fanconi-syndrom og seponering av Acme Product-behandling er viktig for å forhindre start av nedsatt nyrefunksjon og osteomalasi, da syndromet vanligvis er reversibelt. De viktigste tegnene er: proteinuri, glukosuri (med normale blodsukkernivåer), hyperaminoaciduri og fosfaturi (mulig samtidig med hypofosfatemi). Progresjon kan involvere symptomer som polyuri, polydipsi og proksimal muskelsvakhet. I sjeldne tilfeller kan hypofosfatemisk osteomalasi med ikke-lokaliserte skjelettsmerter, forhøyet alkalisk fosfatase i serum og stressfraktuer oppstå. Det er viktig å merke seg at Fanconi-syndrom kan forekomme uten forhøyede kreatininnivåer eller lav glomerulær filtreringshastighet. I tilfelle uklare symptomer skal Fanconi-syndromet vurderes, og egnede undersøkelser må utføres.&lt;/span&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                        &lt;u&gt;
                                            &lt;span lang="NO-BOK"&gt;Leverfunksjon&lt;/span&gt;
                                        &lt;/u&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                        &lt;span lang="NO-BOK"&gt;Acme Product har ikke blitt studert hos pasienter med alvorlig nedsatt leverfunksjon og er kontraindisert hos disse pasientene (se pkt. 4.3).&lt;/span&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                        &lt;u&gt;
                                            &lt;span lang="NO-BOK"/&gt;
                                        &lt;/u&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                        &lt;span lang="NO-BOK"&gt;Det anbefales å overvåke leverfunksjon (ASAT, ALAT, gamma-GT, AP) før behandlingsstart og hver 3. måned deretter, siden økning av leverenzymer har blitt observert hos enkelte pasienter i fase III-studien. Skulle det oppstå en klinisk relevant endring i leverparametrene, spesielt i fravær av alternative forklaringer, bør dosereduksjon eller behandlingsseponering vurderes. &lt;/span&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                        &lt;u&gt;
                                            &lt;span lang="NO-BOK"&gt;Rødme/flushing&lt;/span&gt;
                                        &lt;/u&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                        &lt;span lang="NO-BOK"&gt;Pasienter bør gjøres oppmerksom på at de sannsynligvis vil oppleve rødme de første ukene de tar Acme Product (se pkt. 4.8). &lt;/span&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                        &lt;u&gt;
                                            &lt;span lang="NO-BOK"&gt;Laktose&lt;/span&gt;
                                        &lt;/u&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                        &lt;span lang="NO-BOK"&gt;Acme Product inneholder laktose. Pasienter med sjeldne arvelige problemer med galaktoseintoleranse, total laktasemangel eller glukose-galaktose-malabsorpsjon, bør ikke ta dette legemidlet.&lt;/span&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                &lt;/div&gt;<a name="end-xhtml"></a>
              &lt;/text&gt;
            &lt;/section&gt;
            &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.section">section</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#id">id</a>="beb6b712-37af-432a-901f-ab710741e677"&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.title">title</a>
                     <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="4.5     Interaksjon med andre legemidler og andre former for interaksjon"/&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.code">code</a>&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#CodeableConcept#CodeableConcept.coding">coding</a>&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.system">system</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#uri">value</a>="http://spor.ema.europa.eu/v1/example-sections"/&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.code">code</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="20"/&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.display">display</a>
                           <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="4.5 Interaksjon med andre legemidler og andre former for interaksjon"/&gt;
                &lt;/coding&gt;
              &lt;/code&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.text">text</a>&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//narrative.html#Narrative#Narrative.status">status</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="additional"/&gt;
                &lt;div xmlns="http://www.w3.org/1999/xhtml"&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"/&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                        &lt;span lang="NO-BOK"&gt;Ingen interaksjonsstudier er blitt utført.&lt;/span&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                        &lt;span lang="NO-BOK"&gt;Acme Product bør derfor brukes med forsiktighet i kombinasjon med annen systemisk psoriasisbehandling (f.eks. metotreksat, retinoider, psoralener, ciklosporin, immunsuppressiva eller cytostatika) (se pkt. 4.4). Samtidig bruk av andre fumarsyrederivater under behandlingen med Acme Product bør unngås (topikale eller systemiske). &lt;/span&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                        &lt;span lang="NO-BOK"&gt;Samtidig behandling med nyretoksiske stoffer (f.eks. metotreksat, ciklosporin, aminoglykosider, diuretika, NSAID-er eller litium) kan øke potensialet for nyrebivirkninger (f.eks. proteinuri) hos pasienter som tar Acme Product.&lt;/span&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                        &lt;span lang="NO-BOK"&gt;I tilfelle av alvorlig eller langvarig diaré under behandling med Acme Product, kan absorpsjonen av andre legemidler påvirkes. Forsiktighet bør utvises når legemidler med en smal terapeutisk indeks som krever absorpsjon i tarmen skal foreskrives. Effekten til orale prevensjonsmidler kan være redusert, og bruken av et alternativt barriereprevensjonsmiddel anbefales for å forhindre mulig prevensjonssvikt (se forskrivningsinformasjon for oralt prevensjonsmiddel).&lt;/span&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                        &lt;span lang="NO-BOK"&gt;Inntak av store mengder sterke alkoholholdige drikkevarer (mer enn 30 vol. % alkohol) skal unngås, da dette kan føre til økt oppløsningshastighet for Acme Product og derfor kan øke frekvensen av gastrointestinale bivirkninger.&lt;/span&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                        &lt;span lang="NO-BOK"&gt;Vaksinering under behandling med Acme Product har ikke blitt studert. Immunsuppressjon er en risikofaktor for bruk av levende vaksiner. Risikoen ved vaksinering skal vurderes opp mot fordelen.&lt;/span&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                        &lt;span lang="NO-BOK"&gt;Det finnes ingen tegn på Acme Product-interaksjon med cytokrom P450 og de mest vanlige effluks- og opptakstransportørene, dermed forventes ingen interaksjoner med legemidler som metaboliseres eller transporteres av disse systemene (se pkt. 5.2)&lt;/span&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                &lt;/div&gt;<a name="end-xhtml"></a>
              &lt;/text&gt;
            &lt;/section&gt;
            &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.section">section</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#id">id</a>="b769313d-03f5-4684-bedf-6c423bb88dc5"&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.title">title</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="4.6     Fertilitet, graviditet og amming"/&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.code">code</a>&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#CodeableConcept#CodeableConcept.coding">coding</a>&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.system">system</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#uri">value</a>="http://spor.ema.europa.eu/v1/example-sections"/&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.code">code</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="22"/&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.display">display</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="4.6 Fertilitet, graviditet og amming"/&gt;
                &lt;/coding&gt;
              &lt;/code&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.text">text</a>&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//narrative.html#Narrative#Narrative.status">status</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="additional"/&gt;
                &lt;div xmlns="http://www.w3.org/1999/xhtml"&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoCommentText"&gt;
                                        &lt;u&gt;
                                            &lt;span style="font-size:11.0pt" lang="NO-BOK"/&gt;
                                        &lt;/u&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoCommentText"&gt;
                                        &lt;u&gt;
                                            &lt;span style="font-size:11.0pt" lang="NO-BOK"&gt;Fertile kvinner&lt;/span&gt;
                                        &lt;/u&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoCommentText"&gt;
                                        &lt;span style="font-size:11.0pt" lang="NO-BOK"&gt;Acme Product er ikke anbefalt hos fertile kvinner som ikke bruker egnet prevensjon. Hos pasienter som opplever diaré under Acme Product-behandling, kan effekten av orale prevensjonsmidler være redusert, og det kan være nødvendig med barrieremetoder for prevensjon i tillegg (se pkt. 4.5).&lt;/span&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal" class="MsoCommentText"&gt;
                                        &lt;u&gt;
                                            &lt;span style="font-size:11.0pt" lang="NO-BOK"/&gt;
                                        &lt;/u&gt;
                                    &lt;/p&gt;
                                &lt;/div&gt;<a name="end-xhtml"></a>
              &lt;/text&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.section">section</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#id">id</a>="e60acf54-e90b-4d06-971a-5219abe3df44"&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.title">title</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="Graviditet"/&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.code">code</a>&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#CodeableConcept#CodeableConcept.coding">coding</a>&gt;
                    &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.system">system</a>
                            <a href="http://build.fhir.org/branches/R4B//datatypes.html#uri">value</a>="http://spor.ema.europa.eu/v1/example-sections"/&gt;
                    &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.code">code</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="23"/&gt;
                    &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.display">display</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="Graviditet"/&gt;
                  &lt;/coding&gt;
                &lt;/code&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.text">text</a>&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//narrative.html#Narrative#Narrative.status">status</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="additional"/&gt;
                  &lt;div xmlns="http://www.w3.org/1999/xhtml"&gt;
                                        &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                            &lt;span lang="NO-BOK"&gt;Det foreligger begrenset mengde data på bruk av dimetylfumarat hos gravide kvinner. Studier på dyr har vist reproduksjonstoksisitet (se pkt. 5.3). Acme Product er kontraindisert ved graviditet (se pkt. 4.3). &lt;/span&gt;
                                        &lt;/p&gt;
                                        &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                            &lt;u&gt;
                                                &lt;span lang="NO-BOK"/&gt;
                                            &lt;/u&gt;
                                        &lt;/p&gt;
                                    &lt;/div&gt;<a name="end-xhtml"></a>
                &lt;/text&gt;
              &lt;/section&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.section">section</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#id">id</a>="60cdd509-a45c-4a68-ab36-32bda631bddd"&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.title">title</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="Amming"/&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.code">code</a>&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#CodeableConcept#CodeableConcept.coding">coding</a>&gt;
                    &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.system">system</a>
                            <a href="http://build.fhir.org/branches/R4B//datatypes.html#uri">value</a>="http://spor.ema.europa.eu/v1/example-sections"/&gt;
                    &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.code">code</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="24"/&gt;
                    &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.display">display</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="Amming"/&gt;
                  &lt;/coding&gt;
                &lt;/code&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.text">text</a>&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//narrative.html#Narrative#Narrative.status">status</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="additional"/&gt;
                  &lt;div xmlns="http://www.w3.org/1999/xhtml"&gt;
                                        &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                            &lt;span style="color:black" lang="NO-BOK"&gt;Det er ukjent om &lt;/span&gt;
                                            &lt;span lang="NO-BOK"&gt;dimetylfumarat
                                                &lt;span style="color:black"&gt;/metabolitter blir skilt ut i morsmelk hos mennesker. En risiko for nyfødte eller spedbarn som ammes kan ikke &lt;/span&gt;utelukkes
                                                &lt;span style="color:black"&gt;.&lt;/span&gt;Derfor er Acme Product kontraindisert ved amming (se
pkt. 4.3).
                                            &lt;/span&gt;
                                        &lt;/p&gt;
                                        &lt;p style="line-height:normal" class="MsoCommentText"/&gt;
                                    &lt;/div&gt;<a name="end-xhtml"></a>
                &lt;/text&gt;
              &lt;/section&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.section">section</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#id">id</a>="3edf109d-a075-49d3-9e8e-291af2f7af8a"&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.title">title</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="Fertilitet"/&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.code">code</a>&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#CodeableConcept#CodeableConcept.coding">coding</a>&gt;
                    &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.system">system</a>
                            <a href="http://build.fhir.org/branches/R4B//datatypes.html#uri">value</a>="http://spor.ema.europa.eu/v1/example-sections"/&gt;
                    &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.code">code</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="25"/&gt;
                    &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.display">display</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="Fertilitet"/&gt;
                  &lt;/coding&gt;
                &lt;/code&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.text">text</a>&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//narrative.html#Narrative#Narrative.status">status</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="additional"/&gt;
                  &lt;div xmlns="http://www.w3.org/1999/xhtml"&gt;
                                        &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                            &lt;span lang="NO-BOK"&gt;Det foreligger ingen data for mennesker eller dyr på effekten av Acme Product på fertilitet. &lt;/span&gt;
                                        &lt;/p&gt;
                                        &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                    &lt;/div&gt;<a name="end-xhtml"></a>
                &lt;/text&gt;
              &lt;/section&gt;
            &lt;/section&gt;
            &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.section">section</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#id">id</a>="8ede57fa-b7f5-40aa-8b99-8782edf4914e"&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.title">title</a>
                     <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="4.7     Påvirkning av evnen til å kjøre bil og bruke maskiner"/&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.code">code</a>&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#CodeableConcept#CodeableConcept.coding">coding</a>&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.system">system</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#uri">value</a>="http://spor.ema.europa.eu/v1/example-sections"/&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.code">code</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="26"/&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.display">display</a>
                           <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="4.7 Påvirkning av evnen til å kjøre bil og bruke maskiner"/&gt;
                &lt;/coding&gt;
              &lt;/code&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.text">text</a>&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//narrative.html#Narrative#Narrative.status">status</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="additional"/&gt;
                &lt;div xmlns="http://www.w3.org/1999/xhtml"&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"/&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                        &lt;span lang="NO-BOK"&gt;Det er ikke gjennomført noen studier av evnen til å kjøre bil og bruke maskiner. Acme Product kan ha &lt;/span&gt;
                                        &lt;span lang="NO-BOK"&gt;en &lt;/span&gt;
                                        &lt;span lang="NO-BOK"&gt;liten påvirkning på evnen til å kjøre bil og bruke maskiner. Svimmelhet og tretthet kan forekomme etter administrering av Acme Product (se pkt. 4.8).&lt;/span&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                &lt;/div&gt;<a name="end-xhtml"></a>
              &lt;/text&gt;
            &lt;/section&gt;
            &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.section">section</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#id">id</a>="779ba6b9-7eeb-47ed-891d-8245b11c1093"&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.title">title</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="4.8     Bivirkninger"/&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.code">code</a>&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#CodeableConcept#CodeableConcept.coding">coding</a>&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.system">system</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#uri">value</a>="http://spor.ema.europa.eu/v1/example-sections"/&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.code">code</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="27"/&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.display">display</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="4.8 Bivirkninger"/&gt;
                &lt;/coding&gt;
              &lt;/code&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.text">text</a>&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//narrative.html#Narrative#Narrative.status">status</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="additional"/&gt;
                &lt;div xmlns="http://www.w3.org/1999/xhtml"&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                        &lt;u&gt;
                                            &lt;span lang="NO-BOK"/&gt;
                                        &lt;/u&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                        &lt;u&gt;
                                            &lt;span lang="NO-BOK"&gt;Sammendrag av sikkerhetsprofilen&lt;/span&gt;
                                        &lt;/u&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                        &lt;span lang="NO-BOK"&gt;De vanligste bivirkningene observert med Acme Product i den kliniske fase III-studien (1102) hos psoriasispasienter var gastrointestinale hendelser (62,7 %), rødme (20,8 %) og lymfopeni (10 %). De fleste bivirkningene ble ansett for å være milde og førte ikke til seponering av studiebehandlingen. De eneste bivirkningene som førte til seponering av behandling for &amp;gt;5 % av pasientene var gastrointestinale reaksjoner. For overvåkningsanbefalinger og klinisk håndtering av bivirkninger, se pkt. 4.4. &lt;/span&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                        &lt;u&gt;
                                            &lt;span lang="NO-BOK"&gt;Bivirkningstabell&lt;/span&gt;
                                        &lt;/u&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                        &lt;span lang="NO-BOK"&gt;Følgende er en liste over bivirkninger som pasienter opplevde under behandling med Acme Product i løpet av den kliniske studien og med Fumaderm, et relatert legemiddel som inneholder dimetylfumarat samt andre fumarsyreestere.&lt;/span&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                        &lt;span lang="NO-BOK"&gt;Bivirkningsfrekvensen er definert ved hjelp av følgende konvensjon: svært vanlige (≥ 1/10), vanlige (≥ 1/100 til &amp;lt;1/10), mindre vanlige (≥ 1/1000 til &amp;lt;1/100), sjeldne (≥ 1/10 000 til &amp;lt;1/1000), svært sjeldne (&amp;lt;1/10 000) og ikke kjent (kan ikke anslås utfra tilgjengelige data). &lt;/span&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                    &lt;table border="1" cellpadding="0" cellspacing="0" style="border-collapse:collapse;border:none" class="MsoNormalTable"&gt;
                                        &lt;thead&gt;
                                            &lt;tr&gt;
                                                &lt;td width="207" style="width:155.35pt;border:solid windowtext 1.0pt;     padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                    &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                        &lt;b&gt;
                                                            &lt;span lang="NO-BOK"&gt;Organklassesystem&lt;/span&gt;
                                                        &lt;/b&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td width="206" style="width:2.15in;border:solid windowtext 1.0pt;     border-left:none;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                    &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                        &lt;b&gt;
                                                            &lt;span lang="NO-BOK"&gt;Bivirkninger&lt;/span&gt;
                                                        &lt;/b&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td width="206" style="width:154.2pt;border:solid windowtext 1.0pt;     border-left:none;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                    &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                        &lt;b&gt;
                                                            &lt;span lang="NO-BOK"&gt;Frekvens&lt;/span&gt;
                                                        &lt;/b&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                            &lt;/tr&gt;
                                        &lt;/thead&gt;
                                        &lt;tr&gt;
                                            &lt;td width="207" style="width:155.35pt;border:solid windowtext 1.0pt;    border-top:none;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Infeksiøse og   parasittære sykdommer&lt;/span&gt;
                                                &lt;/p&gt;
                                            &lt;/td&gt;
                                            &lt;td width="206" style="width:2.15in;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Herpes zoster&lt;/span&gt;
                                                &lt;/p&gt;
                                            &lt;/td&gt;
                                            &lt;td width="206" style="width:154.2pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Ikke kjent**&lt;/span&gt;
                                                &lt;/p&gt;
                                            &lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td width="207" style="width:155.35pt;border:solid windowtext 1.0pt;    border-top:none;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Sykdommer i   blod og lymfatiske organer&lt;/span&gt;
                                                &lt;/p&gt;
                                            &lt;/td&gt;
                                            &lt;td width="206" style="width:2.15in;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Lymfopeni&lt;/span&gt;
                                                &lt;/p&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Leukopeni&lt;/span&gt;
                                                &lt;/p&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Eosinofili&lt;/span&gt;
                                                &lt;/p&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Leukocytose&lt;/span&gt;
                                                &lt;/p&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Akutt   lymfatisk leukemi*&lt;/span&gt;
                                                &lt;/p&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Irreversibel   pancytopeni*&lt;/span&gt;
                                                &lt;/p&gt;
                                            &lt;/td&gt;
                                            &lt;td width="206" style="width:154.2pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Svært vanlige&lt;/span&gt;
                                                &lt;/p&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Svært vanlige&lt;/span&gt;
                                                &lt;/p&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Vanlige&lt;/span&gt;
                                                &lt;/p&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Vanlige&lt;/span&gt;
                                                &lt;/p&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Svært sjeldne&lt;/span&gt;
                                                &lt;/p&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Svært sjeldne&lt;/span&gt;
                                                &lt;/p&gt;
                                            &lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td width="207" style="width:155.35pt;border:solid windowtext 1.0pt;    border-top:none;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Stoffskifte-   og ernæringsbetingede sykdommer&lt;/span&gt;
                                                &lt;/p&gt;
                                            &lt;/td&gt;
                                            &lt;td width="206" style="width:2.15in;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Nedsatt   appetitt&lt;/span&gt;
                                                &lt;/p&gt;
                                            &lt;/td&gt;
                                            &lt;td width="206" style="width:154.2pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Vanlige&lt;/span&gt;
                                                &lt;/p&gt;
                                            &lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td width="207" style="width:155.35pt;border:solid windowtext 1.0pt;    border-top:none;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Nevrologiske   sykdommer&lt;/span&gt;
                                                &lt;/p&gt;
                                            &lt;/td&gt;
                                            &lt;td width="206" style="width:2.15in;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Hodepine&lt;/span&gt;
                                                &lt;/p&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Parestesi&lt;/span&gt;
                                                &lt;/p&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Svimmelhet*&lt;/span&gt;
                                                &lt;/p&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Progressiv   multifokal leukoencefalopati&lt;/span&gt;
                                                &lt;/p&gt;
                                            &lt;/td&gt;
                                            &lt;td width="206" style="width:154.2pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Vanlige&lt;/span&gt;
                                                &lt;/p&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Vanlige&lt;/span&gt;
                                                &lt;/p&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Mindre   vanlige&lt;/span&gt;
                                                &lt;/p&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Ikke kjent&lt;/span&gt;
                                                &lt;/p&gt;
                                            &lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td width="207" style="width:155.35pt;border:solid windowtext 1.0pt;    border-top:none;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Karsykdommer&lt;/span&gt;
                                                &lt;/p&gt;
                                            &lt;/td&gt;
                                            &lt;td width="206" style="width:2.15in;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Rødme/flushing&lt;/span&gt;
                                                &lt;/p&gt;
                                            &lt;/td&gt;
                                            &lt;td width="206" style="width:154.2pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Svært vanlige&lt;/span&gt;
                                                &lt;/p&gt;
                                            &lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td width="207" style="width:155.35pt;border:solid windowtext 1.0pt;    border-top:none;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Gastrointestinale   sykdommer&lt;/span&gt;
                                                &lt;/p&gt;
                                            &lt;/td&gt;
                                            &lt;td width="206" style="width:2.15in;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Diaré&lt;/span&gt;
                                                &lt;/p&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Abdominal   distensjon&lt;/span&gt;
                                                &lt;/p&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Magesmerter&lt;/span&gt;
                                                &lt;/p&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Kvalme&lt;/span&gt;
                                                &lt;/p&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Oppkast&lt;/span&gt;
                                                &lt;/p&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Dyspepsi&lt;/span&gt;
                                                &lt;/p&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Forstoppelse&lt;/span&gt;
                                                &lt;/p&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Ubehag i   magen&lt;/span&gt;
                                                &lt;/p&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Flatulens&lt;/span&gt;
                                                &lt;/p&gt;
                                            &lt;/td&gt;
                                            &lt;td width="206" style="width:154.2pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Svært vanlige&lt;/span&gt;
                                                &lt;/p&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Svært vanlige&lt;/span&gt;
                                                &lt;/p&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Svært vanlige&lt;/span&gt;
                                                &lt;/p&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Svært vanlige&lt;/span&gt;
                                                &lt;/p&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Vanlige&lt;/span&gt;
                                                &lt;/p&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Vanlige&lt;/span&gt;
                                                &lt;/p&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Vanlige&lt;/span&gt;
                                                &lt;/p&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Vanlige&lt;/span&gt;
                                                &lt;/p&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Vanlige&lt;/span&gt;
                                                &lt;/p&gt;
                                            &lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td width="207" style="width:155.35pt;border:solid windowtext 1.0pt;    border-top:none;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Hud- og   underhudssykdommer&lt;/span&gt;
                                                &lt;/p&gt;
                                            &lt;/td&gt;
                                            &lt;td width="206" style="width:2.15in;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Erytem&lt;/span&gt;
                                                &lt;/p&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Følelse av   svie i huden&lt;/span&gt;
                                                &lt;/p&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Kløe&lt;/span&gt;
                                                &lt;/p&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Allergisk   hudreaksjon&lt;/span&gt;
                                                &lt;/p&gt;
                                            &lt;/td&gt;
                                            &lt;td width="206" style="width:154.2pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Vanlige&lt;/span&gt;
                                                &lt;/p&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Vanlige&lt;/span&gt;
                                                &lt;/p&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Vanlige&lt;/span&gt;
                                                &lt;/p&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Sjeldne&lt;/span&gt;
                                                &lt;/p&gt;
                                            &lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td width="207" style="width:155.35pt;border:solid windowtext 1.0pt;    border-top:none;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Sykdommer i   nyre og urinveier&lt;/span&gt;
                                                &lt;/p&gt;
                                            &lt;/td&gt;
                                            &lt;td width="206" style="width:2.15in;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Proteinuri&lt;/span&gt;
                                                &lt;/p&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Nyresvikt&lt;/span&gt;
                                                &lt;/p&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Fanconi-syndrom*&lt;/span&gt;
                                                &lt;/p&gt;
                                            &lt;/td&gt;
                                            &lt;td width="206" style="width:154.2pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Mindre   vanlige&lt;/span&gt;
                                                &lt;/p&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Ikke kjent&lt;/span&gt;
                                                &lt;/p&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Ikke kjent&lt;/span&gt;
                                                &lt;/p&gt;
                                            &lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td width="207" style="width:155.35pt;border:solid windowtext 1.0pt;    border-top:none;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Generelle   lidelser og reaksjoner på administrasjonsstedet &lt;/span&gt;
                                                &lt;/p&gt;
                                            &lt;/td&gt;
                                            &lt;td width="206" style="width:2.15in;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Tretthet&lt;/span&gt;
                                                &lt;/p&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Varmefølelse&lt;/span&gt;
                                                &lt;/p&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Asteni&lt;/span&gt;
                                                &lt;/p&gt;
                                            &lt;/td&gt;
                                            &lt;td width="206" style="width:154.2pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Vanlige&lt;/span&gt;
                                                &lt;/p&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Vanlige&lt;/span&gt;
                                                &lt;/p&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Vanlige&lt;/span&gt;
                                                &lt;/p&gt;
                                            &lt;/td&gt;
                                        &lt;/tr&gt;
                                        &lt;tr&gt;
                                            &lt;td width="207" style="width:155.35pt;border:solid windowtext 1.0pt;    border-top:none;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Undersøkelser&lt;/span&gt;
                                                &lt;/p&gt;
                                            &lt;/td&gt;
                                            &lt;td width="206" style="width:2.15in;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Økte   leverenzymer&lt;/span&gt;
                                                &lt;/p&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Økt   serumkreatinin&lt;/span&gt;
                                                &lt;/p&gt;
                                            &lt;/td&gt;
                                            &lt;td width="206" style="width:154.2pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Vanlige&lt;/span&gt;
                                                &lt;/p&gt;
                                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                    &lt;span lang="NO-BOK"&gt;Mindre   vanlige&lt;/span&gt;
                                                &lt;/p&gt;
                                            &lt;/td&gt;
                                        &lt;/tr&gt;
                                    &lt;/table&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                        &lt;span style="font-size:9.0pt" lang="NO-BOK"&gt;* Ytterligere bivirkninger rapportert med Fumaderm, et relatert legemiddel som inneholder dimetylfumarat samt andre fumarsyreestere.&lt;/span&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                        &lt;span style="font-size:9.0pt" lang="NO-BOK"&gt;**Bivirkninger som ble rapportert  etter markedsføring.&lt;/span&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                        &lt;u&gt;
                                            &lt;span lang="NO-BOK"&gt;Beskrivelse av utvalgte bivirkninger&lt;/span&gt;
                                        &lt;/u&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                        &lt;i&gt;
                                            &lt;span lang="NO-BOK"&gt;Gastrointestinale forstyrrelser&lt;/span&gt;
                                        &lt;/i&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                        &lt;span lang="NO-BOK"&gt;Data fra den kliniske fase III-studien samt fra litteratur viser at gastrointestinale sykdommer med dimetylfumaratholdige legemidler mest sannsynlig oppstår i løpet av de første 2 til 3 månedene etter at behandlingen er påbegynt. Ingen klar dosesammenheng  og ingen risikofaktorer for forekomst av disse bivirkningene kunne identifiseres. Diaré var en vanlig bivirkning (36,9 %) blant pasienter som tok Acme Product, og dette førte til at legemidlet ble seponert hos omtrent 10 % av pasientene. Mer enn 9 % av disse diaréhendelsene var av mild til moderat alvorlighetsgrad (se pkt. 4.4).&lt;/span&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                        &lt;i&gt;
                                            &lt;span lang="NO-BOK"&gt;Rødme/flushing&lt;/span&gt;
                                        &lt;/i&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                        &lt;span lang="NO-BOK"&gt;Basert på observasjoner i den klinske fase III-studien samt litteraturdata oppstår rødme oftest i løpet av de første ukene av behandlingen og har en tendens til å reduseres over tid. I den kliniske studien opplevde totalt 20,8 % av pasientene som fikk Acme Product rødme som var mild i de fleste tilfellene (se pkt. 4.4). Publisert klinisk erfaring med dimetylfumaratholdige legemidler viser at individuelle episoder med rødme vanligvis begynner kort tid etter inntak av tablettene og opphører innen noen timer.&lt;/span&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                        &lt;i&gt;
                                            &lt;span lang="NO-BOK"&gt;Hematologiske forandringer&lt;/span&gt;
                                        &lt;/i&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                        &lt;span lang="NO-BOK"&gt;Data fra den kliniske fase III-studien samt fra litteraturen viser
at forandringer i hematologiske parametere mest sannsynlig forekommer i løpet
av de første 3 månedene etter at behandlingen med dimetylfumarat er
påbegynt. Spesielt var det i den kliniske studien en lett reduksjon i
gjennomsnittlige lymfocyttnivåer som begynte mellom uke 3 og 5 og var
maksimal innen uke 12, der omtrent en tredjedel av pasientene hadde
lymfocyttverdier under 1,0 x 10
                                            &lt;sup&gt;9&lt;/sup&gt;/l. Gjennomsnitts- og
medianverdiene for lymfocytter forble innenfor normalområdet i løpet av den
kliniske studien. Ved uke 16 (behandlingsslutt) var det ingen ytterligere
reduksjon i lymfocyttallene. Ved uke 16 av behandlingen ble det vist at 13/175
(7,4 %) av pasientene hadde lymfocyttnivåer &amp;lt;0,7 x 10
                                            &lt;sup&gt;9&lt;/sup&gt;/l. Blodprøvetaking
for kliniske sikkerhetslaboratorietester ved oppfølgingsbesøkene ble kun utført
i tilfelle uregelmessigheter ved forutgående besøk. I løpet av den
behandlingsfrie oppfølgingen ble det observert lymfocyttnivåer på &amp;lt;0,7 x 10
                                            &lt;sup&gt;9&lt;/sup&gt;/l
hos 1/29 (3,5 %) pasienter ved 6 måneder og 0/28 (0 %) ved 12 måneder
etter seponering av behandlingen. Ved 12 måneder etter seponering av
behandlingen hadde 3/28 (10,7 %) pasienter lymfocyttverdier under 1,0 x 10
                                            &lt;sup&gt;9&lt;/sup&gt;/l,
og dette ville representere 3/279 (1,1 %) av pasientene som begynte på
Acme Product.
                                        &lt;/span&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                        &lt;span lang="NO-BOK"&gt;For det totale
leukocyttallet ble en reduksjon vist ved uke 12 av behandlingen, det økte
langsomt igjen ved uke 16 (behandlingsslutt), og 12 måneder etter
seponering av behandlingen hadde alle pasienter verdier over 3,0 x 10
                                            &lt;sup&gt;9&lt;/sup&gt;/l.
                                        &lt;/span&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                        &lt;span lang="NO-BOK"&gt;En forbigående økning i gjennomsnittsverdier for eosinofiler ble observert så tidlig som uke 3, nådde maksimal verdi ved uke 5 og 8,og hadde returnert til baselineverdier ved uke 16.&lt;/span&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                        &lt;span lang="NO-BOK"&gt;For overvåkningsanbefalinger og klinisk håndtering av hematologiske bivirkninger, se pkt 4.4.&lt;/span&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                        &lt;u&gt;
                                            &lt;span lang="NO-BOK"/&gt;
                                        &lt;/u&gt;
                                    &lt;/p&gt;
                                &lt;/div&gt;<a name="end-xhtml"></a>
              &lt;/text&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.section">section</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#id">id</a>="267ecb50-3623-4dbe-8071-840f0ca2889b"&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.title">title</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="Melding av mistenkte bivirkninger"/&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.code">code</a>&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#CodeableConcept#CodeableConcept.coding">coding</a>&gt;
                    &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.system">system</a>
                            <a href="http://build.fhir.org/branches/R4B//datatypes.html#uri">value</a>="http://spor.ema.europa.eu/v1/example-sections"/&gt;
                    &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.code">code</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="29"/&gt;
                    &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.display">display</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="Melding av mistenkte bivirkninger"/&gt;
                  &lt;/coding&gt;
                &lt;/code&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.text">text</a>&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//narrative.html#Narrative#Narrative.status">status</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="additional"/&gt;
                  &lt;div xmlns="http://www.w3.org/1999/xhtml"&gt;
                                        &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                            &lt;span lang="NO-BOK"&gt;Melding av mistenkte bivirkninger etter godkjenning av legemidlet
er viktig. Det gjør det mulig å overvåke forholdet mellom nytte og risiko for
legemidlet kontinuerlig. Helsepersonell oppfordres til å melde enhver mistenkt
bivirkning. Dette gjøres 
                                                &lt;span style="color:black"&gt;via 
                                                    &lt;span style="background:  lightgrey"&gt;det nasjonale meldesystemet som beskrevet i &lt;/span&gt;
                                                &lt;/span&gt;
                                            &lt;/span&gt;
                                            &lt;span lang="EN-GB"&gt;
                                                &lt;a href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"&gt;
                                                    &lt;span style="background:lightgrey"&gt;Appendix V&lt;/span&gt;
                                                &lt;/a&gt;
                                            &lt;/span&gt;
                                            &lt;span lang="NO-BOK"&gt;.&lt;/span&gt;
                                        &lt;/p&gt;
                                        &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"/&gt;
                                    &lt;/div&gt;<a name="end-xhtml"></a>
                &lt;/text&gt;
              &lt;/section&gt;
            &lt;/section&gt;
            &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.section">section</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#id">id</a>="68f3502a-0e58-4cab-a49a-e9c68496e1df"&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.title">title</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="4.9     Overdosering"/&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.code">code</a>&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#CodeableConcept#CodeableConcept.coding">coding</a>&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.system">system</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#uri">value</a>="http://spor.ema.europa.eu/v1/example-sections"/&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.code">code</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="30"/&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.display">display</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="4.9 Overdosering"/&gt;
                &lt;/coding&gt;
              &lt;/code&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.text">text</a>&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//narrative.html#Narrative#Narrative.status">status</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="additional"/&gt;
                &lt;div xmlns="http://www.w3.org/1999/xhtml"&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"/&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                        &lt;span lang="NO-BOK"&gt;Symptomatisk behandling er indisert ved overdosering. Ingen spesifikk motgift er kjent.&lt;/span&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                &lt;/div&gt;<a name="end-xhtml"></a>
              &lt;/text&gt;
            &lt;/section&gt;
          &lt;/section&gt;
          &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.section">section</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#id">id</a>="bfaa811c-6b32-4216-be85-3cb156c82bb2"&gt;
            &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.title">title</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="5.       FARMAKOLOGISKE EGENSKAPER"/&gt;
            &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.code">code</a>&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#CodeableConcept#CodeableConcept.coding">coding</a>&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.system">system</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#uri">value</a>="http://spor.ema.europa.eu/v1/example-sections"/&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.code">code</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="32"/&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.display">display</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="5. FARMAKOLOGISKE EGENSKAPER"/&gt;
              &lt;/coding&gt;
            &lt;/code&gt;
            &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.text">text</a>&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//narrative.html#Narrative#Narrative.status">status</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="additional"/&gt;
              &lt;div xmlns="http://www.w3.org/1999/xhtml"&gt;
                                &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"/&gt;
                            &lt;/div&gt;<a name="end-xhtml"></a>
            &lt;/text&gt;
            &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.section">section</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#id">id</a>="5f641461-bcca-46a8-8bfe-4838ebf7bf99"&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.title">title</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="5.1     Farmakodynamiske egenskaper"/&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.code">code</a>&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#CodeableConcept#CodeableConcept.coding">coding</a>&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.system">system</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#uri">value</a>="http://spor.ema.europa.eu/v1/example-sections"/&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.code">code</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="33"/&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.display">display</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="5.1 Farmakodynamiske egenskaper"/&gt;
                &lt;/coding&gt;
              &lt;/code&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.text">text</a>&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//narrative.html#Narrative#Narrative.status">status</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="additional"/&gt;
                &lt;div xmlns="http://www.w3.org/1999/xhtml"&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"/&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                        &lt;span lang="NO-BOK"&gt;Farmakoteraputisk gruppe: Andre immunsuppressiver, ATC-kode: L04AX07&lt;/span&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                        &lt;u&gt;
                                            &lt;span lang="NO-BOK"/&gt;
                                        &lt;/u&gt;
                                    &lt;/p&gt;
                                &lt;/div&gt;<a name="end-xhtml"></a>
              &lt;/text&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.section">section</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#id">id</a>="5b40031c-aad3-4fc1-b495-9683f84496ec"&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.title">title</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="Virkningsmekanisme"/&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.code">code</a>&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#CodeableConcept#CodeableConcept.coding">coding</a>&gt;
                    &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.system">system</a>
                            <a href="http://build.fhir.org/branches/R4B//datatypes.html#uri">value</a>="http://spor.ema.europa.eu/v1/example-sections"/&gt;
                    &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.code">code</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="34"/&gt;
                    &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.display">display</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="Virkningsmekanisme"/&gt;
                  &lt;/coding&gt;
                &lt;/code&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.text">text</a>&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//narrative.html#Narrative#Narrative.status">status</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="additional"/&gt;
                  &lt;div xmlns="http://www.w3.org/1999/xhtml"&gt;
                                        &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                            &lt;span lang="NO-BOK"&gt;De antiinflammatoriske og immunmodulerende effektene av dimetylfumarat og dets metabolitt monometylfumarat er ikke fullt ut klarlagt, men antas hovedsakelig å være grunnet interaksjon med intracellulært redusert glutation i celler som er direkte involvert i patogenesen ved psoriasis. Denne interaksjonen med glutation fører til hemming av translokasjon inn i kjernen, og den transkripsjonelle aktiviteten til nukleær faktor kappa-lettkjede-enhancer av aktiverte B-celler (NF-κB). &lt;/span&gt;
                                        &lt;/p&gt;
                                        &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                        &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                            &lt;span lang="NO-BOK"&gt;Den primære aktiviteten av dimetylfumarat og monometylfumarat anses å være immunmodulerende, noe som resulterer i en endring av T-hjelperceller (Th) fra Th1- og Th17-profil til en Th2-fenotype. Inflammatorisk cytokinproduksjon reduseres ved induksjon av proapoptotiske hendelser, hemming av keratinocytt-proliferasjon, redusert uttrykk av adhesjonsmolekyler og redusert inflammatorisk infiltrat i psoriasisplakk. &lt;/span&gt;
                                        &lt;/p&gt;
                                        &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                            &lt;u&gt;
                                                &lt;span lang="NO-BOK"/&gt;
                                            &lt;/u&gt;
                                        &lt;/p&gt;
                                    &lt;/div&gt;<a name="end-xhtml"></a>
                &lt;/text&gt;
              &lt;/section&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.section">section</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#id">id</a>="16cf40c8-e667-431a-a1b0-8dc621a4a1c3"&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.title">title</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="Klinisk effekt og sikkerhet"/&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.code">code</a>&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#CodeableConcept#CodeableConcept.coding">coding</a>&gt;
                    &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.system">system</a>
                            <a href="http://build.fhir.org/branches/R4B//datatypes.html#uri">value</a>="http://spor.ema.europa.eu/v1/example-sections"/&gt;
                    &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.code">code</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="36"/&gt;
                    &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.display">display</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="Klinisk effekt og sikkerhet"/&gt;
                  &lt;/coding&gt;
                &lt;/code&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.text">text</a>&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//narrative.html#Narrative#Narrative.status">status</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="additional"/&gt;
                  &lt;div xmlns="http://www.w3.org/1999/xhtml"&gt;
                                        &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                            &lt;span lang="NO-BOK"&gt;Sikkerhet og effekt av Acme Product ble undersøkt i en dobbeltblindet, 3-armet fase III-studie (1102) med placebo og aktiv komparator&lt;/span&gt;
                                            &lt;span lang="NO-BOK"&gt;kontroll&lt;/span&gt;
                                            &lt;span lang="NO-BOK"&gt;med pasienter med moderat til alvorlig plakkpsoriasis (studie 1102). I studien ble 704 pasienter  randomisert til Acme Product, en aktiv komparator (Fumaderm, et kombinasjonspreparat med samme innhold av dimetylfumarat pluss 3 monoetylfumaratsalter) og placebo i et forhold på 2:2:1. Pasienter begynte behandling med tabletter med innhold 30 mg/dag dimetylfumarat eller placebo, og titrering opp til maksimalt 720 mg/dag i begge aktive behandlingsarmer som beskrevet i pkt. 4.2. Dersom behandlingseffekt ble observert før maksimaldosen på dimetylfumarat 720 mg/dag var nådd, var det unødvendig med en ytterligere økning av dosen, og dosen skulle reduseres jevnt til en individuell vedlikeholdsdose. Ved individuell intolerabilitet ved økt dosering i løpet av uke 4 til 16, skulle pasienten gå tilbake til den siste tolererte dosen tatt siden start av uke 4, og som skulle opprettholdes inntil slutten av behandlingsperioden (uke 16). Pasientene mottok behandling i opp til 16 uker og oppfølgingsbesøk var planlagt for opp til 12 måneder etter avsluttet behandling.&lt;/span&gt;
                                        &lt;/p&gt;
                                        &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                        &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                            &lt;span lang="NO-BOK"&gt;Det var god balanse i demografiske og baselineparametre mellom behandlingsgruppene. Av de 699 pasientene var de fleste var kaukasiere (99 %) og menn (65 %), og gjennomsnittsalderen var 44 år. De fleste pasientene (91 %) var &amp;lt;65 år. De fleste pasientene hadde moderat psoriasis basert på PASI-skår for psoriasisområde og alvorlighetsgrad (Psoriasis Area and Severity Index) og PGAI-skår for legens totalvurdering (Physician’s Global Assessment) ved baseline: gjennomsnittlig PASI-skår ved baseline var 16,35 og 60 % av pasientene ble scoret som moderat på PGA. Flertallet av pasientene rapporterte en &amp;quot;svært høy&amp;quot; eller &amp;quot;ekstremt høy&amp;quot; påvirkning av psoriasis på sitt liv basert på Dermatologisk livskvalitetsindeks (DLQI), med en gjennomsnittlig DLQI-skår på 11,5. &lt;/span&gt;
                                        &lt;/p&gt;
                                        &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                        &lt;p style="line-height:normal;text-autospace:none" class="MsoNormal"&gt;
                                            &lt;span lang="NO-BOK"&gt;Etter 16 ukers behandling ble Acme Product funnet å være bedre enn placebo (p &amp;lt;0,0001) basert på PASI 75 og PGA-skår på helet eller nesten tilhelet, og ikke dårligere (ved bruk av en non-inferioritymargin på 15 %) enn den aktive komparatoren (p &amp;lt;0,0003) basert på PASI 75.&lt;/span&gt;
                                        &lt;/p&gt;
                                        &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                        &lt;table border="0" cellpadding="0" cellspacing="0" width="612" style="border-collapse:collapse" class="MsoNormalTable"&gt;
                                            &lt;tr&gt;
                                                &lt;td colspan="7" width="612" style="width:459.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                                        &lt;b&gt;
                                                            &lt;span style="font-size:10.0pt" lang="NO-BOK"&gt;Oppsummering av klinisk effekt etter 16   ukers behandling i studie 1102&lt;/span&gt;
                                                        &lt;/b&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td width="272" style="width:203.85pt;border:none;border-top:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                                        &lt;b&gt;
                                                            &lt;span style="font-size:10.0pt" lang="NO-BOK"&gt;Vurdering&lt;/span&gt;
                                                        &lt;/b&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td colspan="2" width="123" style="width:92.15pt;border:none;    border-top:solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"&gt;
                                                        &lt;b&gt;
                                                            &lt;span style="font-size:10.0pt" lang="EN-GB"&gt;Acme Product&lt;/span&gt;
                                                        &lt;/b&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td colspan="3" width="95" style="width:70.9pt;border:none;border-top:    solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"&gt;
                                                        &lt;b&gt;
                                                            &lt;span style="font-size:10.0pt" lang="EN-GB"&gt;Placebo&lt;/span&gt;
                                                        &lt;/b&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td width="123" style="width:92.1pt;border:none;border-top:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"&gt;
                                                        &lt;b&gt;
                                                            &lt;span style="font-size:10.0pt" lang="EN-GB"&gt;Fumaderm&lt;/span&gt;
                                                        &lt;/b&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td width="272" style="width:203.85pt;border:none;border-bottom:    solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"/&gt;
                                                &lt;/td&gt;
                                                &lt;td colspan="2" width="123" style="width:92.15pt;border:none;    border-bottom:solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"&gt;
                                                        &lt;b&gt;
                                                            &lt;span style="font-size:10.0pt" lang="EN-GB"&gt;N=267&lt;/span&gt;
                                                        &lt;/b&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td colspan="3" width="95" style="width:70.9pt;border:none;border-bottom:    solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"&gt;
                                                        &lt;b&gt;
                                                            &lt;span style="font-size:10.0pt" lang="EN-GB"&gt;N=131&lt;/span&gt;
                                                        &lt;/b&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td width="123" style="width:92.1pt;border:none;border-bottom:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"&gt;
                                                        &lt;b&gt;
                                                            &lt;span style="font-size:10.0pt" lang="EN-GB"&gt;N=273&lt;/span&gt;
                                                        &lt;/b&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td colspan="7" width="612" style="width:459.0pt;border:none;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                                        &lt;b&gt;
                                                            &lt;span style="font-size:10.0pt" lang="NO-BOK"&gt;Superiority testing kontra placebo&lt;/span&gt;
                                                        &lt;/b&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td width="272" style="width:203.85pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                    &lt;p style="text-align:justify;text-justify:inter-ideograph;    line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                                        &lt;b&gt;
                                                            &lt;span style="font-size:10.0pt" lang="NO-BOK"&gt;PASI 75&lt;/span&gt;
                                                        &lt;/b&gt;
                                                        &lt;span style="font-size:10.0pt" lang="NO-BOK"&gt;, n (%)&lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td colspan="2" width="123" style="width:92.15pt;padding:1.4pt 5.4pt 1.4pt 5.4pt"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"&gt;
                                                        &lt;span style="font-size:10.0pt" lang="EN-GB"&gt;100 (37,5)&lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td colspan="3" width="95" style="width:70.9pt;padding:1.4pt 5.4pt 1.4pt 5.4pt"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"&gt;
                                                        &lt;span style="font-size:10.0pt" lang="EN-GB"&gt;20 (15,3)&lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td width="123" style="width:92.1pt;padding:1.4pt 5.4pt 1.4pt 5.4pt"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"&gt;
                                                        &lt;span style="font-size:10.0pt" lang="EN-GB"&gt;110 (40,3)&lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td width="272" style="width:203.85pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                    &lt;p style="margin-left:7.1pt;line-height:normal;page-break-after:    avoid" class="MsoNormal"&gt;
                                                        &lt;span style="font-size:10.0pt" lang="NO-BOK"&gt;p-verdi&lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td colspan="3" width="170" style="width:127.6pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                    &lt;p style="margin-right:15.85pt;text-align:right;    line-height:normal" align="right" class="MsoNormal"&gt;
                                                        &lt;span style="font-size:10.0pt" lang="EN-GB"&gt;&amp;lt;0,0001
                                                            &lt;sup&gt;a&lt;/sup&gt;
                                                        &lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td colspan="3" width="170" style="width:127.55pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                    &lt;p style="margin-left:15.85pt;line-height:normal" class="MsoNormal"&gt;
                                                        &lt;span style="font-size:10.0pt" lang="EN-GB"&gt;&amp;lt;0,0001
                                                            &lt;sup&gt;a&lt;/sup&gt;
                                                        &lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td width="272" style="width:203.85pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                                        &lt;b&gt;
                                                            &lt;span style="font-size:10.0pt" lang="SV"&gt;Tosidig 99,24 % KI&lt;/span&gt;
                                                        &lt;/b&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td colspan="3" width="170" style="width:127.6pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                    &lt;p style="margin-right:14.2pt;text-align:right;    line-height:normal;page-break-after:avoid" align="right" class="MsoNormal"&gt;
                                                        &lt;span style="font-size:    10.0pt" lang="IT"&gt;10,7, 33,7
                                                            &lt;sup&gt;a&lt;/sup&gt;
                                                        &lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td colspan="3" width="170" style="width:127.55pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                    &lt;p style="margin-left:8.75pt;line-height:normal" class="MsoNormal"&gt;
                                                        &lt;span style="font-size:10.0pt" lang="IT"&gt;13,5, 36,6&lt;/span&gt;
                                                        &lt;sup&gt;
                                                            &lt;span style="font-size:10.0pt" lang="EN-GB"&gt;a&lt;/span&gt;
                                                        &lt;/sup&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td width="272" style="width:203.85pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                                        &lt;b&gt;
                                                            &lt;span style="font-size:10.0pt" lang="NO-BOK"&gt;PGA-skår helet eller nesten helet,&lt;/span&gt;
                                                        &lt;/b&gt;
                                                        &lt;span style="font-size:10.0pt" lang="NO-BOK"&gt;n (%)&lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td colspan="2" width="123" style="width:92.15pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"&gt;
                                                        &lt;span style="font-size:10.0pt" lang="EN-GB"&gt;88 (33,0)&lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td colspan="3" width="95" style="width:70.9pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"&gt;
                                                        &lt;span style="font-size:10.0pt" lang="EN-GB"&gt;17 (13,0)&lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td width="123" style="width:92.1pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"&gt;
                                                        &lt;span style="font-size:10.0pt" lang="EN-GB"&gt;102 (37,4)&lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td width="272" style="width:203.85pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                    &lt;p style="margin-left:7.1pt;line-height:normal;page-break-after:    avoid" class="MsoNormal"&gt;
                                                        &lt;span style="font-size:10.0pt" lang="NO-BOK"&gt;p-verdi&lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td colspan="3" width="170" style="width:127.6pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                    &lt;p style="margin-right:15.85pt;text-align:right;    line-height:normal" align="right" class="MsoNormal"&gt;
                                                        &lt;span style="font-size:10.0pt" lang="EN-GB"&gt;&amp;lt;0,0001
                                                            &lt;sup&gt;a&lt;/sup&gt;
                                                        &lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td colspan="3" width="170" style="width:127.55pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                    &lt;p style="margin-left:15.85pt;line-height:normal" class="MsoNormal"&gt;
                                                        &lt;span style="font-size:10.0pt" lang="EN-GB"&gt;&amp;lt;0,0001
                                                            &lt;sup&gt;a&lt;/sup&gt;
                                                        &lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td width="272" style="width:203.85pt;border:none;border-bottom:    solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                    &lt;p style="margin-left:7.1pt;line-height:normal;page-break-after:    avoid" class="MsoNormal"&gt;
                                                        &lt;span style="font-size:10.0pt" lang="EN-GB"&gt;Tosidig 99.24%KI&lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td colspan="3" width="170" style="width:127.6pt;border:none;    border-bottom:solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                    &lt;p style="margin-right:14.2pt;text-align:right;    line-height:normal;page-break-after:avoid" align="right" class="MsoNormal"&gt;
                                                        &lt;span style="font-size:    10.0pt" lang="EN-GB"&gt;9,0, 31,0
                                                            &lt;sup&gt;a&lt;/sup&gt;
                                                        &lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td colspan="3" width="170" style="width:127.55pt;border:none;    border-bottom:solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                    &lt;p style="margin-left:8.75pt;line-height:normal" class="MsoNormal"&gt;
                                                        &lt;span style="font-size:10.0pt" lang="EN-GB"&gt;13,3, 35,5
                                                            &lt;sup&gt;a&lt;/sup&gt;
                                                        &lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td colspan="2" width="319" style="width:239.3pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"/&gt;
                                                &lt;/td&gt;
                                                &lt;td colspan="3" width="142" style="width:106.3pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"&gt;
                                                        &lt;b&gt;
                                                            &lt;span style="font-size:10.0pt" lang="EN-GB"&gt;Acme Product&lt;/span&gt;
                                                        &lt;/b&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td colspan="2" width="151" style="width:113.4pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"&gt;
                                                        &lt;b&gt;
                                                            &lt;span style="font-size:10.0pt" lang="EN-GB"&gt;Fumaderm&lt;/span&gt;
                                                        &lt;/b&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td colspan="2" width="319" style="width:239.3pt;border:none;    border-bottom:solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"/&gt;
                                                &lt;/td&gt;
                                                &lt;td colspan="3" width="142" style="width:106.3pt;border:none;    border-bottom:solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"&gt;
                                                        &lt;b&gt;
                                                            &lt;span style="font-size:10.0pt" lang="EN-GB"&gt;N=267&lt;/span&gt;
                                                        &lt;/b&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td colspan="2" width="151" style="width:113.4pt;border:none;    border-bottom:solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"&gt;
                                                        &lt;b&gt;
                                                            &lt;span style="font-size:10.0pt" lang="EN-GB"&gt;N=273&lt;/span&gt;
                                                        &lt;/b&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td colspan="2" width="319" style="width:239.3pt;border:none;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                    &lt;p style="margin-left:7.1pt;line-height:normal;page-break-after:    avoid" class="MsoNormal"&gt;
                                                        &lt;b&gt;
                                                            &lt;span style="font-size:10.0pt" lang="EN-GB"&gt;Non-inferiority av   Acme Product kontra Fumaderm&lt;/span&gt;
                                                        &lt;/b&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td colspan="3" width="142" style="width:106.3pt;border:none;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"/&gt;
                                                &lt;/td&gt;
                                                &lt;td colspan="2" width="151" style="width:113.4pt;border:none;padding:1.4pt 5.4pt 1.4pt 5.4pt"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"/&gt;
                                                &lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td colspan="2" width="319" style="width:239.3pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                    &lt;p style="margin-left:7.1pt;line-height:normal;page-break-after:    avoid" class="MsoNormal"&gt;
                                                        &lt;b&gt;
                                                            &lt;span style="font-size:10.0pt" lang="EN-GB"&gt;PASI 75&lt;/span&gt;
                                                        &lt;/b&gt;
                                                        &lt;span style="font-size:10.0pt" lang="EN-GB"&gt;, n (%)&lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td colspan="3" width="142" style="width:106.3pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"&gt;
                                                        &lt;span style="font-size:10.0pt" lang="EN-GB"&gt;100 (37,5)&lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td colspan="2" width="151" style="width:113.4pt;padding:1.4pt 5.4pt 1.4pt 5.4pt"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"&gt;
                                                        &lt;span style="font-size:10.0pt" lang="EN-GB"&gt;110 (40,3)&lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td colspan="2" width="319" style="width:239.3pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                    &lt;p style="margin-left:7.1pt;line-height:normal;page-break-after:    avoid" class="MsoNormal"&gt;
                                                        &lt;span style="font-size:10.0pt" lang="EN-GB"&gt;p-verdi&lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td colspan="5" width="293" style="width:219.7pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"&gt;
                                                        &lt;span style="font-size:10.0pt" lang="EN-GB"&gt;0,0003
                                                            &lt;sup&gt;b&lt;/sup&gt;
                                                        &lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td colspan="2" width="319" style="width:239.3pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                    &lt;p style="margin-left:7.1pt;line-height:normal;page-break-after:    avoid" class="MsoNormal"&gt;
                                                        &lt;span style="font-size:10.0pt" lang="NO-BOK"&gt;Ensidig 97,5 % gjentatt KI   (nedre grense)&lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td colspan="5" width="293" style="width:219.7pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"&gt;
                                                        &lt;span style="font-size:10.0pt" lang="EN-GB"&gt;-11,6
                                                            &lt;sup&gt;b&lt;/sup&gt;
                                                        &lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td colspan="2" width="319" style="width:239.3pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                    &lt;p style="margin-left:7.1pt;line-height:normal;page-break-after:    avoid" class="MsoNormal"&gt;
                                                        &lt;b&gt;
                                                            &lt;span style="font-size:10.0pt" lang="NO-BOK"&gt;PGA-skår helet eller   nesten helet &lt;/span&gt;
                                                        &lt;/b&gt;
                                                        &lt;span style="font-size:10.0pt" lang="NO-BOK"&gt;n (%)&lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td colspan="3" width="142" style="width:106.3pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"&gt;
                                                        &lt;span style="font-size:10.0pt" lang="EN-GB"&gt;88 (33,0)&lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td colspan="2" width="151" style="width:113.4pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"&gt;
                                                        &lt;span style="font-size:10.0pt" lang="EN-GB"&gt;102 (37,4)&lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td colspan="2" width="319" style="width:239.3pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                    &lt;p style="margin-left:7.1pt;line-height:normal;page-break-after:    avoid" class="MsoNormal"&gt;
                                                        &lt;span style="font-size:10.0pt" lang="EN-GB"&gt;p-verdi&lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td colspan="5" width="293" style="width:219.7pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"&gt;
                                                        &lt;span style="font-size:10.0pt" lang="EN-GB"&gt;0,0007
                                                            &lt;sup&gt;b&lt;/sup&gt;
                                                        &lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td colspan="2" width="319" style="width:239.3pt;border:none;    border-bottom:solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                    &lt;p style="margin-left:7.1pt;line-height:normal;page-break-after:    avoid" class="MsoNormal"&gt;
                                                        &lt;span style="font-size:10.0pt" lang="NO-BOK"&gt;Ensidig 97,5 % gjentatt KI   (nedre grense)&lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                                &lt;td colspan="5" width="293" style="width:219.7pt;border:none;    border-bottom:solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top"&gt;
                                                    &lt;p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"&gt;
                                                        &lt;span style="font-size:10.0pt" lang="EN-GB"&gt;13,0
                                                            &lt;sup&gt;b&lt;/sup&gt;
                                                        &lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr&gt;
                                                &lt;td colspan="7" width="612" style="width:459.0pt;border:none;    padding:0in 5.4pt 0in 5.4pt" valign="top"&gt;
                                                    &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                                        &lt;span style="font-size:9.0pt" lang="NO-BOK"&gt;Fumaderm = Aktiv komparator = et kombinasjonspreparat   med samme innhold av dimetylfumarat pluss 3 monoetylhydrogenfumaratsalter;&lt;/span&gt;
                                                        &lt;span style="font-size:9.0pt" lang="NO-BOK"&gt;n &lt;/span&gt;
                                                        &lt;span style="font-size:9.0pt" lang="NO-BOK"&gt;= &lt;/span&gt;
                                                        &lt;span style="font-size:    9.0pt" lang="NO-BOK"&gt;antall pasienter med tilgjengelige data&lt;/span&gt;
                                                        &lt;span style="font-size:9.0pt" lang="NO-BOK"&gt;;&lt;/span&gt;
                                                        &lt;span style="font-size:9.0pt" lang="NO-BOK"&gt;N &lt;/span&gt;
                                                        &lt;span style="font-size:9.0pt" lang="NO-BOK"&gt;= &lt;/span&gt;
                                                        &lt;span style="font-size:9.0pt" lang="NO-BOK"&gt;antall &lt;/span&gt;
                                                        &lt;span style="font-size:9.0pt" lang="NO-BOK"&gt;pasienter&lt;/span&gt;
                                                        &lt;span style="font-size:    9.0pt" lang="NO-BOK"&gt;i &lt;/span&gt;
                                                        &lt;span style="font-size:9.0pt" lang="NO-BOK"&gt;populasjon&lt;/span&gt;
                                                        &lt;span style="font-size:9.0pt" lang="NO-BOK"&gt;; PASI &lt;/span&gt;
                                                        &lt;span style="font-size:9.0pt" lang="NO-BOK"&gt;= &lt;/span&gt;
                                                        &lt;span style="font-size:    9.0pt" lang="NO-BOK"&gt;Psoriasis Area Severity Index&lt;/span&gt;
                                                        &lt;span style="font-size:9.0pt" lang="NO-BOK"&gt;;&lt;/span&gt;
                                                        &lt;span style="font-size:9.0pt" lang="NO-BOK"&gt;PGA &lt;/span&gt;
                                                        &lt;span style="font-size:9.0pt" lang="NO-BOK"&gt;= &lt;/span&gt;
                                                        &lt;span style="font-size:9.0pt" lang="NO-BOK"&gt;Physician’s Global Assessment&lt;/span&gt;
                                                        &lt;span style="font-size:9.0pt" lang="NO-BOK"&gt;; 
                                                            &lt;sup&gt;a&lt;/sup&gt;Overlegenhet for
Acme Product kontra placebo med en differanse på 22,2 % for PASI 75 og 20,0 %
for PGA-skår helet eller nesten helet, overlegenhet av Fumaderm kontra
placebo med en differanse på 25,0 % for PASI og 24,4 % for PGA-skår helet eller
nesten helet.
                                                            &lt;sup&gt;b&lt;/sup&gt;Non-inferiority  av Acme Product kontra Fumaderm med
en differanse på -2,8 % for PASI 75 og -4,4 % for PGA-skår helet eller nesten
helet.
                                                        &lt;/span&gt;
                                                    &lt;/p&gt;
                                                &lt;/td&gt;
                                            &lt;/tr&gt;
                                            &lt;tr height="0"&gt;
                                                &lt;td width="272" style="border:none"/&gt;
                                                &lt;td width="47" style="border:none"/&gt;
                                                &lt;td width="76" style="border:none"/&gt;
                                                &lt;td width="47" style="border:none"/&gt;
                                                &lt;td width="19" style="border:none"/&gt;
                                                &lt;td width="28" style="border:none"/&gt;
                                                &lt;td width="123" style="border:none"/&gt;
                                            &lt;/tr&gt;
                                        &lt;/table&gt;
                                        &lt;p style="line-height:normal;text-autospace:none" class="MsoNormal"/&gt;
                                        &lt;p style="line-height:normal;text-autospace:none" class="MsoNormal"&gt;
                                            &lt;span lang="NO-BOK"&gt;Det var en trend i effektendepunktet PASI-skår gjennomsnittlig -% endring fra baseline, som indikerte begynnelsen av klinisk respons på Acme Product så tidlig som uke 3 (-11,8 %) som ble statistisk signifikant sammenlignet med placebo innen uke 8 (-30,9 %). Ytterligere forbedring ble sett innen uke 16 (-50,8 %).&lt;/span&gt;
                                        &lt;/p&gt;
                                        &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                            &lt;a name="_Ref431313822"/&gt;
                                        &lt;/p&gt;
                                        &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                            &lt;span lang="NO-BOK"&gt;Fordelene ved behandling med Acme Product ble også støttet av pasientenes selvopplevde forbedringer i livskvaliteten. I uke 16 hadde pasienter som ble behandlet med Acme Product en lavere gjennomsnittlig DLQI sammenlignet med placebo (5,4 kontra 8,8). &lt;/span&gt;
                                        &lt;/p&gt;
                                        &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                        &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                            &lt;span lang="NO-BOK"&gt;Tilbakefall (definert som forverring på &amp;gt;125 % av baseline PASI-verdi) ble vurdert etter 2 måneder uten behandling og viste seg å ikke være et klinisk problem med fumarsyreestere, da det ble dokumentert hos svært få pasienter (Acme Product 1,1 % og aktiv komparator 2,2 %, sammenlignet med 9,3 % i placebogruppen).&lt;/span&gt;
                                        &lt;/p&gt;
                                        &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                        &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                            &lt;span lang="NO-BOK"&gt;Langsiktige effektdata er for tiden ikke tilgjengelige for Acme Product, men i farmakokinetiske og kliniske studier viste systemisk eksponering, effekt og sikkerhet seg å være sammenlignbare for Acme Product og den aktive komparatoren som inneholder dimetylfumarat. Dermed er det rimelig å forvente at langsiktig effekt også er sammenlignbar for Acme Product og dimetylfumaratholdige legemidler. Opprettholdelse av langsiktig effekt har blitt godt beskrevet for andre dimetylfumaratholdige legemidler, og derfor kan det forventes at behandlingsfordelene som ses med Acme Product ved uke 16, opprettholdes hos pasienter som behandles på lang sikt, i minst 24 måneder.&lt;/span&gt;
                                        &lt;/p&gt;
                                        &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                    &lt;/div&gt;<a name="end-xhtml"></a>
                &lt;/text&gt;
              &lt;/section&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.section">section</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#id">id</a>="b54479b6-e871-407c-af15-0aba326b4513"&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.title">title</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="Pediatrisk populasjon"/&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.code">code</a>&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#CodeableConcept#CodeableConcept.coding">coding</a>&gt;
                    &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.system">system</a>
                            <a href="http://build.fhir.org/branches/R4B//datatypes.html#uri">value</a>="http://spor.ema.europa.eu/v1/example-sections"/&gt;
                    &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.code">code</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="37"/&gt;
                    &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.display">display</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="Pediatrisk populasjon"/&gt;
                  &lt;/coding&gt;
                &lt;/code&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.text">text</a>&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//narrative.html#Narrative#Narrative.status">status</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="additional"/&gt;
                  &lt;div xmlns="http://www.w3.org/1999/xhtml"&gt;
                                        &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                            &lt;span lang="NO-BOK"&gt;Det europeiske legemiddelkontoret har gitt unntak fra forpliktelsen til å presentere resultater fra studier med Acme Product i alle undergrupper av den pediatriske populasjonen ved denne indikasjonen (se pkt. 4.2 for informasjon om pediatrisk bruk).&lt;/span&gt;
                                        &lt;/p&gt;
                                        &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                    &lt;/div&gt;<a name="end-xhtml"></a>
                &lt;/text&gt;
              &lt;/section&gt;
            &lt;/section&gt;
            &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.section">section</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#id">id</a>="a41f9de8-182e-456c-b2ef-e1d03a91da29"&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.title">title</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="5.2     Farmakokinetiske egenskaper"/&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.code">code</a>&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#CodeableConcept#CodeableConcept.coding">coding</a>&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.system">system</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#uri">value</a>="http://spor.ema.europa.eu/v1/example-sections"/&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.code">code</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="38"/&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.display">display</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="5.2 Farmakokinetiske egenskaper"/&gt;
                &lt;/coding&gt;
              &lt;/code&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.text">text</a>&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//narrative.html#Narrative#Narrative.status">status</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="additional"/&gt;
                &lt;div xmlns="http://www.w3.org/1999/xhtml"&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                        &lt;u&gt;
                                            &lt;span lang="NO-BOK"/&gt;
                                        &lt;/u&gt;
                                    &lt;/p&gt;
                                &lt;/div&gt;<a name="end-xhtml"></a>
              &lt;/text&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.section">section</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#id">id</a>="59ed6059-97ef-4228-b72b-7167ecbe8213"&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.title">title</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="Absorpsjon"/&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.code">code</a>&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#CodeableConcept#CodeableConcept.coding">coding</a>&gt;
                    &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.system">system</a>
                            <a href="http://build.fhir.org/branches/R4B//datatypes.html#uri">value</a>="http://spor.ema.europa.eu/v1/example-sections"/&gt;
                    &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.code">code</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="39"/&gt;
                    &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.display">display</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="Absorpsjon"/&gt;
                  &lt;/coding&gt;
                &lt;/code&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.text">text</a>&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//narrative.html#Narrative#Narrative.status">status</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="additional"/&gt;
                  &lt;div xmlns="http://www.w3.org/1999/xhtml"&gt;
                                        &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                            &lt;span lang="NO-BOK"&gt;Etter oral administrasjon påvises ikke dimetylfumarat i plasma fordi det raskt hydrolyseres av esteraser til sin aktive metabolitt monometylfumarat. Etter oral administrering av en enkelt tablett Acme Product på 120 mg til friske forsøkspersoner, nådde monometylfumarat maksimal plasmakonsentrasjoner på rundt 1325 ng/ml og 1311 ng/ml etter henholdsvis faste og matinntak. Når Acme Product tas sammen med mat &lt;/span&gt;
                                            &lt;span lang="NO-BOK"&gt;forsinkes&lt;/span&gt;
                                            &lt;span lang="NO-BOK"&gt;t
                                                &lt;sub&gt;max&lt;/sub&gt;for monometylfumarat fra 3,5 til 9,0 timer.
                                            &lt;/span&gt;
                                        &lt;/p&gt;
                                        &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                    &lt;/div&gt;<a name="end-xhtml"></a>
                &lt;/text&gt;
              &lt;/section&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.section">section</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#id">id</a>="a2dd0a8f-9f20-425e-baa7-3d807b818e6b"&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.title">title</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="Distribusjon"/&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.code">code</a>&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#CodeableConcept#CodeableConcept.coding">coding</a>&gt;
                    &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.system">system</a>
                            <a href="http://build.fhir.org/branches/R4B//datatypes.html#uri">value</a>="http://spor.ema.europa.eu/v1/example-sections"/&gt;
                    &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.code">code</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="40"/&gt;
                    &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.display">display</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="Distribusjon"/&gt;
                  &lt;/coding&gt;
                &lt;/code&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.text">text</a>&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//narrative.html#Narrative#Narrative.status">status</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="additional"/&gt;
                  &lt;div xmlns="http://www.w3.org/1999/xhtml"&gt;
                                        &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                            &lt;span lang="NO-BOK"&gt;Plasmaproteinbindingen av monometylfumarat er omkring 50 %. Dimetylfumarat viser ikke noen bindingsaffinitet til serumproteiner som ytterligere kan bidra til dets hurtige eliminasjon fra sirkulasjonen. &lt;/span&gt;
                                        &lt;/p&gt;
                                        &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                    &lt;/div&gt;<a name="end-xhtml"></a>
                &lt;/text&gt;
              &lt;/section&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.section">section</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#id">id</a>="564cb153-58a2-49ee-a6e2-bd5a5a9ae05f"&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.title">title</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="Biotransformasjon"/&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.code">code</a>&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#CodeableConcept#CodeableConcept.coding">coding</a>&gt;
                    &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.system">system</a>
                            <a href="http://build.fhir.org/branches/R4B//datatypes.html#uri">value</a>="http://spor.ema.europa.eu/v1/example-sections"/&gt;
                    &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.code">code</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="41"/&gt;
                    &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.display">display</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="Biotransformasjon"/&gt;
                  &lt;/coding&gt;
                &lt;/code&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.text">text</a>&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//narrative.html#Narrative#Narrative.status">status</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="additional"/&gt;
                  &lt;div xmlns="http://www.w3.org/1999/xhtml"&gt;
                                        &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                            &lt;span lang="NO-BOK"&gt;Biotransformasjonen av dimetylfumarat involverer ikke cytokrom
P450-isoenzymer. 
                                                &lt;i&gt;In vitro&lt;/i&gt;-studier har vist at monometylfumarat ved
terapeutisk dose ikke hemmer eller induserer noen av cytokrom P450-enzymene,
den er ikke et substrat eller hemmer av P-glykoprotein og er ikke en hemmer av
de mest vanlige effluks- og opptakstransportørene.
                                                &lt;i&gt;In vitro&lt;/i&gt;-studier har
vist at dimetylfumarat ved en terapeutisk dose ikke hemmer CYP3A4/5 og BCRP og
er en svak P-glykoproteininibitor.
                                            &lt;/span&gt;
                                        &lt;/p&gt;
                                        &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                        &lt;p style="line-height:normal" id="7fa270b4-18aa-4b54-961c-e77d0a6b05b8" class="MsoNormal"/&gt;
                                        &lt;i&gt;
                                            &lt;span lang="NO-BOK"&gt;In vitro&lt;/span&gt;
                                        &lt;/i&gt;
                                        &lt;none/&gt;
                                        &lt;p style="line-height:normal" id="7fa270b4-18aa-4b54-961c-e77d0a6b05b8" class="MsoNormal"&gt;
                                            &lt;span lang="NO-BOK"&gt;-studier har vist at hydrolyse av dimetylfumarat til monometylfumarat skjer raskt ved pH&nbsp;8 (pH i tynntarmen), men ikke ved pH&nbsp;1 (pH i magesekken). En del av det totale dimetylfumaratet blir hydrolysert av esteraser og tynntarmens alkaliske miljø, mens resten kommer inn i portveneblodet. Videre studier har vist at dimetylfumarat (og i mindre grad monometylfumarat) reagerer delvis med redusert glutation som danner en glutationforbindelse. Disse forbindelsene ble påvist i dyrestudier i tarmslimhinner hos rotter og i mindre grad i portveneblod. Ukonjugert dimetylfumarat kan imidlertid ikke påvises i plasma hos dyr eller psoriasispasienter etter oral administrering. Derimot kan ukonjugert monometylfumarat påvises i plasma. Videre metabolisme skjer ved oksideringen via trikarboksylsyresyklusen, som danner karbondioksid og vann. &lt;/span&gt;
                                        &lt;/p&gt;
                                        &lt;p style="margin-right:-.1pt;line-height:normal" class="MsoNormal"&gt;
                                            &lt;u&gt;
                                                &lt;span lang="NO-BOK"/&gt;
                                            &lt;/u&gt;
                                        &lt;/p&gt;
                                    &lt;/div&gt;<a name="end-xhtml"></a>
                &lt;/text&gt;
              &lt;/section&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.section">section</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#id">id</a>="ecca1616-154d-4478-91e8-cf9be6418312"&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.title">title</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="Eliminasjon"/&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.code">code</a>&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#CodeableConcept#CodeableConcept.coding">coding</a>&gt;
                    &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.system">system</a>
                            <a href="http://build.fhir.org/branches/R4B//datatypes.html#uri">value</a>="http://spor.ema.europa.eu/v1/example-sections"/&gt;
                    &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.code">code</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="42"/&gt;
                    &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.display">display</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="Eliminasjon"/&gt;
                  &lt;/coding&gt;
                &lt;/code&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.text">text</a>&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//narrative.html#Narrative#Narrative.status">status</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="additional"/&gt;
                  &lt;div xmlns="http://www.w3.org/1999/xhtml"&gt;
                                        &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                            &lt;span lang="NO-BOK"&gt;Utånding av CO
                                                &lt;sub&gt;2&lt;/sub&gt;som følge av monometylfumaratets
metabolisme er den primære eliminasjonsveien. Bare små mengder intakt
monometylfumarat skilles ut gjennom urin eller avføring. Den delen av
dimetylfumaratet som reagerer med glutation, med dannelse av en
glutationforbindelse, metaboliseres videre til merkaptopurinsyre, som utskilles
i urinen.
                                            &lt;/span&gt;
                                        &lt;/p&gt;
                                        &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                        &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                            &lt;span lang="NO-BOK"&gt;Den tilsynelatende terminale eliminasjonshalveringstiden for monometylfumaratet er omtrent 2 timer.&lt;/span&gt;
                                        &lt;/p&gt;
                                        &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                    &lt;/div&gt;<a name="end-xhtml"></a>
                &lt;/text&gt;
              &lt;/section&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.section">section</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#id">id</a>="91f77a7f-6acc-4ef9-8796-7d1e20bd8325"&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.title">title</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="Linearitet/ikke-linearitet"/&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.code">code</a>&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#CodeableConcept#CodeableConcept.coding">coding</a>&gt;
                    &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.system">system</a>
                            <a href="http://build.fhir.org/branches/R4B//datatypes.html#uri">value</a>="http://spor.ema.europa.eu/v1/example-sections"/&gt;
                    &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.code">code</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="43"/&gt;
                    &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.display">display</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="Linearitet/ikke-linearitet"/&gt;
                  &lt;/coding&gt;
                &lt;/code&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.text">text</a>&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//narrative.html#Narrative#Narrative.status">status</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="additional"/&gt;
                  &lt;div xmlns="http://www.w3.org/1999/xhtml"&gt;
                                        &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                            &lt;span lang="NO-BOK"&gt;Til tross for høy variasjon mellom pasienter, var eksponeringen
målt som AUC og C
                                                &lt;sub&gt;max&lt;/sub&gt;, generelt doseproporsjonal etter administrering
av enkeltdoser på 4 x 30 mg dimetylfumarat tabletter (total dose på 120 mg)
og 2 x 120 mg dimetylfumarat tabletter (total dose på 240 mg).
                                            &lt;/span&gt;
                                        &lt;/p&gt;
                                        &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                            &lt;u&gt;
                                                &lt;span lang="NO-BOK"/&gt;
                                            &lt;/u&gt;
                                        &lt;/p&gt;
                                        &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                            &lt;u&gt;
                                                &lt;span lang="NO-BOK"&gt;Nedsatt nyrefunksjon&lt;/span&gt;
                                            &lt;/u&gt;
                                        &lt;/p&gt;
                                        &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                            &lt;span lang="NO-BOK"&gt;Ingen spesifikke studier har blitt utført hos pasienter med nedsatt nyrefunksjon. Men fordi eliminasjon via nyrene spiller en mindre rolle for totalclearance fra plasma, er det usannsynlig at nedsatt nyrefunksjon kan påvirke de farmakokinetiske egenskapene til Acme Product (se pkt. 4.2). &lt;/span&gt;
                                        &lt;/p&gt;
                                        &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                        &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                            &lt;u&gt;
                                                &lt;span lang="NO-BOK"&gt;Nedsatt leverfunksjon&lt;/span&gt;
                                            &lt;/u&gt;
                                        &lt;/p&gt;
                                        &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                            &lt;span lang="NO-BOK"&gt;Ingen spesifikke studier har blitt utført hos pasienter med nedsatt leverfunksjon. Men ettersom dimetylfumarat metaboliseres av esteraser og det alkaliske miljøet i tynntarmen uten at cytokrom P450 er involvert, forventes det ikke at nedsatt leverfunksjon påvirker eksponering (se pkt. 4.2). &lt;/span&gt;
                                        &lt;/p&gt;
                                        &lt;p style="margin-right:-.1pt;line-height:normal" class="MsoNormal"/&gt;
                                    &lt;/div&gt;<a name="end-xhtml"></a>
                &lt;/text&gt;
              &lt;/section&gt;
            &lt;/section&gt;
            &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.section">section</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#id">id</a>="c83d8044-45f8-43dc-b493-e9f29a019451"&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.title">title</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="5.3     Prekliniske sikkerhetsdata"/&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.code">code</a>&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#CodeableConcept#CodeableConcept.coding">coding</a>&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.system">system</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#uri">value</a>="http://spor.ema.europa.eu/v1/example-sections"/&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.code">code</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="45"/&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.display">display</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="5.3 Prekliniske sikkerhetsdata"/&gt;
                &lt;/coding&gt;
              &lt;/code&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.text">text</a>&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//narrative.html#Narrative#Narrative.status">status</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="additional"/&gt;
                &lt;div xmlns="http://www.w3.org/1999/xhtml"&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"/&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                        &lt;span lang="NO-BOK"&gt;Prekliniske sikkerhetsfarmakologi- og gentoksisitetsdata indikerer ingen spesiell fare for mennesker.&lt;/span&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                        &lt;u&gt;
                                            &lt;span lang="NO-BOK"&gt;Toksikologi&lt;/span&gt;
                                        &lt;/u&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                        &lt;span lang="NO-BOK"&gt;Nyrene ble identifisert som et viktig målorgan for toksisitet i
prekliniske studier. Nyrefunn hos hunder omfattet minimal til moderat tubulær hypertrofi,
økt forekomst og alvorlighetsgrad av tubulær vakuolisering og minimal til liten
degenerering av nyretubuli, og dette ble ansett som toksikologisk relevant. Høyeste
nivå uten observerte bivirkninger (NOAEL, no‑observed
adverse-effect-level) etter 3 måneders behandling var 30 mg/kg/dag, noe
som tilsvarer 2,9 ganger og 9,5 ganger human systemisk eksponering
ved høyeste anbefalte dose (720 mg/dag), for henholdsvis AUC- og C
                                            &lt;sub&gt;max&lt;/sub&gt;-verdier.
                                        &lt;/span&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                        &lt;u&gt;
                                            &lt;span lang="NO-BOK"&gt;Reproduksjonstoksisitet &lt;/span&gt;
                                        &lt;/u&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                        &lt;span lang="NO-BOK"&gt;Ingen studier av fertilitet eller pre- og postnatal utvikling er blitt utført med Acme Product.&lt;/span&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                        &lt;span lang="NO-BOK"&gt;Det var ingen
effekt på fostervekt eller misdannelser som kunne knyttes til maternelt inntak
av dimetylfumarat under studien av embryoføtal utvikling hos rotter. Imidlertid
var det en økning i antall fostre med avvikene &amp;quot;ekstra leverlapp&amp;quot; og
&amp;quot;unormal hoftekamjustering&amp;quot; med maternelt toksiske doser. NOAEL for
maternell og embryoføtal toksisitet var 40 mg/kg/dag, som tilsvarer 0,2 ganger
og 2,0 ganger human systemisk eksponering ved høyeste anbefalte dose
(720 mg/dag), for henholdsvis AUC- og C
                                            &lt;sub&gt;max&lt;/sub&gt;-verdier.
                                        &lt;/span&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                        &lt;span lang="NO-BOK"&gt;Det er vist at dimetylfumarat passerer placentamembranen til føtalt blod hos rotter.&lt;/span&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                        &lt;u&gt;
                                            &lt;span lang="NO-BOK"&gt;Karsinogenisitet&lt;/span&gt;
                                        &lt;/u&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                        &lt;span lang="NO-BOK"&gt;Ingen karsinogenisitetsstudier er utført for Acme Product. Basert på tilgjengelige data som indikerer at fumarsyreestere kan aktivere cellulære mekanismer relatert til utvikling av nyretumorer, kan en potensiell tumorigen aktivitet av eksogent administrert dimetylfumarat på nyrene ikke utelukkes.&lt;/span&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                &lt;/div&gt;<a name="end-xhtml"></a>
              &lt;/text&gt;
            &lt;/section&gt;
          &lt;/section&gt;
          &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.section">section</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#id">id</a>="d3f0286b-3050-4928-b713-0294beb4cb15"&gt;
            &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.title">title</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="6.       FARMASØYTISKE OPPLYSNINGER"/&gt;
            &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.code">code</a>&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#CodeableConcept#CodeableConcept.coding">coding</a>&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.system">system</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#uri">value</a>="http://spor.ema.europa.eu/v1/example-sections"/&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.code">code</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="47"/&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.display">display</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="6. FARMASØYTISKE OPPLYSNINGER"/&gt;
              &lt;/coding&gt;
            &lt;/code&gt;
            &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.text">text</a>&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//narrative.html#Narrative#Narrative.status">status</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="additional"/&gt;
              &lt;div xmlns="http://www.w3.org/1999/xhtml"&gt;
                                &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"/&gt;
                                &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                    &lt;b&gt;
                                        &lt;span lang="NO-BOK"&gt;6.1     Fortegnelse over hjelpestoffer&lt;/span&gt;
                                    &lt;/b&gt;
                                &lt;/p&gt;
                                &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"/&gt;
                                &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                    &lt;u&gt;
                                        &lt;span lang="NO-BOK"&gt;Acme Product 30 mg og Acme Product 120 mg&lt;/span&gt;
                                    &lt;/u&gt;
                                &lt;/p&gt;
                                &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                    &lt;i&gt;
                                        &lt;span lang="NO-BOK"&gt;Kjerne:&lt;/span&gt;
                                    &lt;/i&gt;
                                &lt;/p&gt;
                                &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                    &lt;span lang="NO-BOK"&gt;Laktosemonohydrat&lt;/span&gt;
                                &lt;/p&gt;
                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                    &lt;span lang="NO-BOK"&gt;Mikrokrystallinsk cellulose&lt;/span&gt;
                                &lt;/p&gt;
                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                    &lt;span lang="NO-BOK"&gt;Krysskarmellosenatrium&lt;/span&gt;
                                &lt;/p&gt;
                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                    &lt;span lang="NO-BOK"&gt;Kolloidal vannfri silika&lt;/span&gt;
                                &lt;/p&gt;
                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                    &lt;span lang="NO-BOK"&gt;Magnesiumstearat&lt;/span&gt;
                                &lt;/p&gt;
                                &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                    &lt;u&gt;
                                        &lt;span lang="NO-BOK"&gt;Acme Product 30 mg&lt;/span&gt;
                                    &lt;/u&gt;
                                &lt;/p&gt;
                                &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                    &lt;i&gt;
                                        &lt;span lang="NO-BOK"&gt;Drasjering:&lt;/span&gt;
                                    &lt;/i&gt;
                                &lt;/p&gt;
                                &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                    &lt;span lang="NO-BOK"&gt;Metakrylsyreetylakrylatkopolymer (1:1) &lt;/span&gt;
                                &lt;/p&gt;
                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                    &lt;span lang="NO-BOK"&gt;Talkum&lt;/span&gt;
                                &lt;/p&gt;
                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                    &lt;span lang="NO-BOK"&gt;Trietylsitrat&lt;/span&gt;
                                &lt;/p&gt;
                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                    &lt;span lang="NO-BOK"&gt;Titandioksid (E171)&lt;/span&gt;
                                &lt;/p&gt;
                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                    &lt;span lang="NO-BOK"&gt;Simetikon&lt;/span&gt;
                                &lt;/p&gt;
                                &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                    &lt;u&gt;
                                        &lt;span lang="NO-BOK"&gt;Acme Product 120 mg&lt;/span&gt;
                                    &lt;/u&gt;
                                &lt;/p&gt;
                                &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                    &lt;i&gt;
                                        &lt;span lang="NO-BOK"&gt;Drasjering:&lt;/span&gt;
                                    &lt;/i&gt;
                                &lt;/p&gt;
                                &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                    &lt;span lang="NO-BOK"&gt;Metakrylsyreetylakrylatkopolymer (1:1) &lt;/span&gt;
                                &lt;/p&gt;
                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                    &lt;span lang="NO-BOK"&gt;Talkum&lt;/span&gt;
                                &lt;/p&gt;
                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                    &lt;span lang="NO-BOK"&gt;Trietylsitrat&lt;/span&gt;
                                &lt;/p&gt;
                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                    &lt;span lang="NO-BOK"&gt;Titandioksid (E171)&lt;/span&gt;
                                &lt;/p&gt;
                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                    &lt;span lang="NO-BOK"&gt;Simetikon&lt;/span&gt;
                                &lt;/p&gt;
                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                    &lt;span lang="NO-BOK"&gt;Indigokarmin (E132)&lt;/span&gt;
                                &lt;/p&gt;
                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                    &lt;span lang="NO-BOK"&gt;Natriumhydroksid&lt;/span&gt;
                                &lt;/p&gt;
                                &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                            &lt;/div&gt;<a name="end-xhtml"></a>
            &lt;/text&gt;
            &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.section">section</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#id">id</a>="9c73367e-0062-48a7-a22c-325e1df72da9"&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.title">title</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="6.2     Uforlikeligheter"/&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.code">code</a>&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#CodeableConcept#CodeableConcept.coding">coding</a>&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.system">system</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#uri">value</a>="http://spor.ema.europa.eu/v1/example-sections"/&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.code">code</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="49"/&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.display">display</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="6.2 Uforlikeligheter"/&gt;
                &lt;/coding&gt;
              &lt;/code&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.text">text</a>&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//narrative.html#Narrative#Narrative.status">status</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="additional"/&gt;
                &lt;div xmlns="http://www.w3.org/1999/xhtml"&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"/&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                        &lt;span lang="NO-BOK"&gt;Ikke relevant.&lt;/span&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                &lt;/div&gt;<a name="end-xhtml"></a>
              &lt;/text&gt;
            &lt;/section&gt;
            &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.section">section</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#id">id</a>="c5de1b87-c384-4acd-b513-358efd62c979"&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.title">title</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="6.3     Holdbarhet"/&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.code">code</a>&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#CodeableConcept#CodeableConcept.coding">coding</a>&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.system">system</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#uri">value</a>="http://spor.ema.europa.eu/v1/example-sections"/&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.code">code</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="50"/&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.display">display</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="6.3 Holdbarhet"/&gt;
                &lt;/coding&gt;
              &lt;/code&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.text">text</a>&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//narrative.html#Narrative#Narrative.status">status</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="additional"/&gt;
                &lt;div xmlns="http://www.w3.org/1999/xhtml"&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"/&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                        &lt;span lang="NO-BOK"&gt;3 år.&lt;/span&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                &lt;/div&gt;<a name="end-xhtml"></a>
              &lt;/text&gt;
            &lt;/section&gt;
            &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.section">section</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#id">id</a>="09bc5d7a-aa2b-4030-bbf0-186dc3872257"&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.title">title</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="6.4     Oppbevaringsbetingelser"/&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.code">code</a>&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#CodeableConcept#CodeableConcept.coding">coding</a>&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.system">system</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#uri">value</a>="http://spor.ema.europa.eu/v1/example-sections"/&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.code">code</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="51"/&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.display">display</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="6.4 Oppbevaringsbetingelser"/&gt;
                &lt;/coding&gt;
              &lt;/code&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.text">text</a>&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//narrative.html#Narrative#Narrative.status">status</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="additional"/&gt;
                &lt;div xmlns="http://www.w3.org/1999/xhtml"&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"/&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                        &lt;span lang="NO-BOK"&gt;Dette legemidlet krever ingen spesielle oppbevaringsbetingelser.&lt;/span&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                &lt;/div&gt;<a name="end-xhtml"></a>
              &lt;/text&gt;
            &lt;/section&gt;
            &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.section">section</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#id">id</a>="788b714e-99f5-4838-9d3d-c2278e3e5f06"&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.title">title</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="6.5     Emballasje (type og innhold)"/&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.code">code</a>&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#CodeableConcept#CodeableConcept.coding">coding</a>&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.system">system</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#uri">value</a>="http://spor.ema.europa.eu/v1/example-sections"/&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.code">code</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="52"/&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.display">display</a>
                           <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="6.5 Emballasje (type og innhold) &amp;lt;og spesielt utstyr for bruk, administrering eller implantasjon&amp;gt;"/&gt;
                &lt;/coding&gt;
              &lt;/code&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.text">text</a>&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//narrative.html#Narrative#Narrative.status">status</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="additional"/&gt;
                &lt;div xmlns="http://www.w3.org/1999/xhtml"&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"/&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                        &lt;u&gt;
                                            &lt;span lang="NO-BOK"&gt;Acme Product 30 mg&lt;/span&gt;
                                        &lt;/u&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                        &lt;span lang="NO-BOK"&gt;42, 70 og 210 enterotabletter i PVC/PVDC blisterpakninger av aluminium. &lt;/span&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                        &lt;u&gt;
                                            &lt;span lang="NO-BOK"&gt;Acme Product 120 mg&lt;/span&gt;
                                        &lt;/u&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                        &lt;span lang="NO-BOK"&gt;40, 70, 90, 100, 120, 180, 200, 240, 300, 360 og 400 enterotabletter i PVC/PVDC blisterpakninger av aluminium.&lt;/span&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                        &lt;span lang="NO-BOK"&gt;Ikke alle pakningsstørrelser vil nødvendigvis bli markedsført.&lt;/span&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                &lt;/div&gt;<a name="end-xhtml"></a>
              &lt;/text&gt;
            &lt;/section&gt;
            &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.section">section</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#id">id</a>="08b14b4e-bbe6-426c-be2c-0c9e1b6b6347"&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.title">title</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="6.6     Spesielle forholdsregler for destruksjon"/&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.code">code</a>&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#CodeableConcept#CodeableConcept.coding">coding</a>&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.system">system</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#uri">value</a>="http://spor.ema.europa.eu/v1/example-sections"/&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.code">code</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="53"/&gt;
                  &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.display">display</a>
                           <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="6.6 Spesielle forholdsregler for destruksjon &amp;lt;og annen håndtering&amp;gt;"/&gt;
                &lt;/coding&gt;
              &lt;/code&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.text">text</a>&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//narrative.html#Narrative#Narrative.status">status</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="additional"/&gt;
                &lt;div xmlns="http://www.w3.org/1999/xhtml"&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"/&gt;
                                    &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                        &lt;span lang="NO-BOK"&gt;Ingen spesielle forholdsregler for destruksjon.&lt;/span&gt;
                                    &lt;/p&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                    &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                &lt;/div&gt;<a name="end-xhtml"></a>
              &lt;/text&gt;
            &lt;/section&gt;
          &lt;/section&gt;
          &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.section">section</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#id">id</a>="ab1e079a-7e7b-459a-9687-94a2a7b20abe"&gt;
            &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.title">title</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="7.       INNEHAVER AV MARKEDSFØRINGSTILLATELSEN"/&gt;
            &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.code">code</a>&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#CodeableConcept#CodeableConcept.coding">coding</a>&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.system">system</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#uri">value</a>="http://spor.ema.europa.eu/v1/example-sections"/&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.code">code</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="55"/&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.display">display</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="7. INNEHAVER AV MARKEDSFØRINGSTILLATELSEN"/&gt;
              &lt;/coding&gt;
            &lt;/code&gt;
            &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.text">text</a>&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//narrative.html#Narrative#Narrative.status">status</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="additional"/&gt;
              &lt;div xmlns="http://www.w3.org/1999/xhtml"&gt;
                                &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"/&gt;
                                &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                    &lt;span lang="NO-BOK"&gt;Almirall, S.A.&lt;/span&gt;
                                &lt;/p&gt;
                                &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                    &lt;span lang="NO-BOK"&gt;Ronda General Mitre, 151&lt;/span&gt;
                                &lt;/p&gt;
                                &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                    &lt;span lang="NO-BOK"&gt;08022 Barcelona&lt;/span&gt;
                                &lt;/p&gt;
                                &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                    &lt;span lang="NO-BOK"&gt;Spania&lt;/span&gt;
                                &lt;/p&gt;
                                &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                            &lt;/div&gt;<a name="end-xhtml"></a>
            &lt;/text&gt;
          &lt;/section&gt;
          &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.section">section</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#id">id</a>="e2f48221-aa2b-4a2a-828a-6a1fe1926ff8"&gt;
            &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.title">title</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="8.       MARKEDSFØRINGSTILLATELSESNUMMER (NUMRE)"/&gt;
            &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.code">code</a>&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#CodeableConcept#CodeableConcept.coding">coding</a>&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.system">system</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#uri">value</a>="http://spor.ema.europa.eu/v1/example-sections"/&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.code">code</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="56"/&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.display">display</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="8. MARKEDSFØRINGSTILLATELSESNUMMER (NUMRE)"/&gt;
              &lt;/coding&gt;
            &lt;/code&gt;
            &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.text">text</a>&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//narrative.html#Narrative#Narrative.status">status</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="additional"/&gt;
              &lt;div xmlns="http://www.w3.org/1999/xhtml"&gt;
                                &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"/&gt;
                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                    &lt;span lang="ES"&gt;EU/1/17/1201/001
                                        &lt;br/&gt;
EU/1/17/1201/002
                                        &lt;br/&gt;
EU/1/17/1201/003
                                        &lt;br/&gt;
EU/1/17/1201/004
                                        &lt;br/&gt;
EU/1/17/1201/005
                                        &lt;br/&gt;
EU/1/17/1201/006
                                        &lt;br/&gt;
                                    &lt;/span&gt;
                                    &lt;span lang="ES"&gt;EU/1/17/1201/007
                                        &lt;br/&gt;
                                    &lt;/span&gt;
                                    &lt;span lang="ES"&gt;EU/1/17/1201/008
                                        &lt;br/&gt;
EU/1/17/1201/009
                                        &lt;br/&gt;
                                    &lt;/span&gt;
                                    &lt;span lang="ES"&gt;EU/1/17/1201/010
                                        &lt;br/&gt;
EU/1/17/1201/011
                                    &lt;/span&gt;
                                &lt;/p&gt;
                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                    &lt;span lang="ES"&gt;EU/1/17/1201/012&lt;/span&gt;
                                &lt;/p&gt;
                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                    &lt;span lang="ES"&gt;EU/1/17/1201/013&lt;/span&gt;
                                &lt;/p&gt;
                                &lt;p style="line-height:normal" class="MsoNormal"&gt;
                                    &lt;span lang="ES"&gt;EU/1/17/1201/014&lt;/span&gt;
                                &lt;/p&gt;
                                &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                            &lt;/div&gt;<a name="end-xhtml"></a>
            &lt;/text&gt;
          &lt;/section&gt;
          &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.section">section</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#id">id</a>="5b69e508-14f8-46fe-8eb4-e9bc863b2fd7"&gt;
            &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.title">title</a>
                   <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="9.       DATO FOR FØRSTE MARKEDSFØRINGSTILLATELSE /SISTE FORNYELSE"/&gt;
            &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.code">code</a>&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#CodeableConcept#CodeableConcept.coding">coding</a>&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.system">system</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#uri">value</a>="http://spor.ema.europa.eu/v1/example-sections"/&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.code">code</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="57"/&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.display">display</a>
                         <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="9. DATO FOR FØRSTE MARKEDSFØRINGSTILLATELSE / SISTE FORNYELSE"/&gt;
              &lt;/coding&gt;
            &lt;/code&gt;
            &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.text">text</a>&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//narrative.html#Narrative#Narrative.status">status</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="additional"/&gt;
              &lt;div xmlns="http://www.w3.org/1999/xhtml"&gt;
                                &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"/&gt;
                                &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                    &lt;span lang="NO-BOK"&gt;Dato for første markedsføringstillatelse: 23. juni 2017&lt;/span&gt;
                                &lt;/p&gt;
                                &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                                &lt;p style="line-height:normal" class="MsoNormal"/&gt;
                            &lt;/div&gt;<a name="end-xhtml"></a>
            &lt;/text&gt;
          &lt;/section&gt;
          &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.section">section</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#id">id</a>="0293fe81-3702-4b3b-94fa-4c478cfb6da6"&gt;
            &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.title">title</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="10.     OPPDATERINGSDATO"/&gt;
            &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.code">code</a>&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#CodeableConcept#CodeableConcept.coding">coding</a>&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.system">system</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#uri">value</a>="http://spor.ema.europa.eu/v1/example-sections"/&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.code">code</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="58"/&gt;
                &lt;<a href="http://build.fhir.org/branches/R4B//datatypes.html#Coding#Coding.display">display</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#string">value</a>="10. OPPDATERINGSDATO"/&gt;
              &lt;/coding&gt;
            &lt;/code&gt;
            &lt;<a href="http://build.fhir.org/branches/R4B//composition.html#Composition.section.text">text</a>&gt;
              &lt;<a href="http://build.fhir.org/branches/R4B//narrative.html#Narrative#Narrative.status">status</a> <a href="http://build.fhir.org/branches/R4B//datatypes.html#code">value</a>="additional"/&gt;
              &lt;div xmlns="http://www.w3.org/1999/xhtml"&gt;
                                &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"/&gt;
                                &lt;p style="line-height:normal;page-break-after:avoid" class="MsoNormal"&gt;
                                    &lt;span lang="NO-BOK"&gt;Detaljert informasjon er tilgjengelig på nettstedet til Det europeiske legemiddelkontoret (The European Medicines Agency) &lt;/span&gt;
                                    &lt;span lang="EN-GB"&gt;
                                        &lt;a href="http://www.ema.europa.eu"&gt;
                                            &lt;span lang="NO-BOK"&gt;http://www.ema.europa.eu&lt;/span&gt;
                                        &lt;/a&gt;
                                    &lt;/span&gt;
                                    &lt;span style="color:blue" lang="NO-BOK"&gt;.&lt;/span&gt;
                                &lt;/p&gt;
                                &lt;p style="margin-right:-.1pt;line-height:normal" class="MsoNormal"/&gt;
                                &lt;span style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;,serif" lang="NO-BOK"&gt;
                                    &lt;br clear="all" style="page-break-before:always"/&gt;
                                &lt;/span&gt;
                            &lt;/div&gt;<a name="end-xhtml"></a>
            &lt;/text&gt;
          &lt;/section&gt;
        &lt;/section&gt;
      &lt;/Composition&gt;
    &lt;/resource&gt;
  &lt;/entry&gt;
&lt;/Bundle&gt;</code></pre>


    <!-- insert notes if present -->
  



</div>
        </div>    <!-- /inner-wrapper -->
      </div>    <!-- /row -->
    </div>    <!-- /container -->
  </div>    <!-- /segment-content -->

  <script src="assets/js/jquery.js" type="text/javascript"> </script>       <!-- note keep space here, otherwise it will be transformed to empty tag -> fails -->
  <script src="assets/js/jquery-ui.min.js" type="text/javascript"> </script>

  <script type="text/javascript">
    $(document).ready(function(){
      if(window.location.hash != "") {
          $('a[href="' + window.location.hash + '"]').click()
      }
    });
  </script>
  <a name="bottom"> </a>
  <div igtool="footer" id="segment-footer" class="segment">    <!-- segment-footer -->
    <div class="container">    <!-- container -->

      <div class="inner-wrapper">
        <p><a name="l2686">​</a>
          IG &copy; 2021+ <a style="color:var(--footer-hyperlink-text-color)" href="https://www.gravitatehealth.eu/"></a>.  Package hl7.eu.fhir.gh#0.1.0 based on <a style="color: var(--footer-hyperlink-text-color)" href="http://build.fhir.org/">FHIR 4.1.0</a>. Generated <span title="Sat, Sep 11, 2021 18:22+0000">2021-09-11</span>
          <br/>
          <span style="color: var(--footer-highlight-text-color)"></span>
            <div style="color: #33333">
	Links: <a style="color: #81BEF7" href="toc.html">Table of Contents</a> |
	<a style="color: #81BEF7" href="qa.html">QA Report</a>
	  <!-- <a style="color: #81BEF7" target="_blank" href="http://hl7.eu/fhir/ig/gravitate-health/history.html">Version History <img alt="external" style="vertical-align: baseline" src="external.png"/></a></a> | -->
	<a rel="license" style="color: #81BEF7" href="http://build.fhir.org/license.html">
		<img src="cc0.png" alt="CC0" style="border-style: none;"/>
	</a>
	  <!-- <a style="color: #81BEF7" href="todo.html">Search</a> | -->
	  <!-- <a style="color: #81BEF7" target="_blank" href="mailto:mail@hl7belgium.org">Propose a change<img alt="external" style="vertical-align: baseline" src="external.png"/></a> -->
	  <!-- <br/>				 
				 <a style="color: #81BEF7" rel="eufunded" href="https://europa.eu"><img style="border-style: none;" alt="EU" src="assets/images/en_horizontal_cef_logo.png" width="250"/></a> -->
	<div id="container width=100% style=&quot;display:block;&quot; ">
		<div style="float: left; padding-top: 17px; padding-bottom: 17px;">The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.<br/>
			This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.</div>
		<div style="float: right; width: 69px; vertical-align:middle; text-align:center; padding-top: 17px; padding-bottom: 17px;">
			<img src="assets/images/eu.png" alt="a EU funded project" height="41"/>
		</div>
	</div>
	<div>
	</div>
</div>
          
        </p>
      </div>    <!-- /inner-wrapper -->
    </div>    <!-- /container -->
  </div>    <!-- /segment-footer -->
  
  <div id="segment-post-footer" class="segment hidden">    <!-- segment-post-footer -->
    <div class="container">    <!-- container -->
    </div>    <!-- /container -->
  </div>    <!-- /segment-post-footer -->
  
    <!-- JS and analytics only. -->
    <!-- Bootstrap core JavaScript
  ================================================== -->
    <!-- Placed at the end of the document so the pages load faster -->
  <script src="assets/js/bootstrap.min.js" type="text/javascript"> </script>
  <script src="assets/js/respond.min.js" type="text/javascript"> </script>
  <script src="assets/js/anchor.min.js" type="text/javascript"> </script>
  <script>anchors.options.visible = 'hover'
anchors.add()</script>
  
  <!-- feedback form - Google forms -->
  <!-- v0.1, 2021-01-09 -->



  <!-- / feedback form -->

    <!-- Analytics Below
  ================================================== -->
  </body>
</html>